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Introduction 
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INTRODUCTION: 
 „Metabolic syndrome‟1 is a constellation of metabolic derangements 
such as, abdominal obesity, hypertension, insulin resistance, hyperinsulinemia, 
impaired glucose tolerance, dyslipidemia, proinflammatory and prothrombotic 
states as well. It is the disorder reaching epidemic proportions worldwide in 
recent times
2
.  
  The recently anticipated global prevalence of metabolic syndrome is 
approximately 16%
3
. It was also found that prevalence as 23.7%
4
 in United 
States heeding to third National Health and Nutrition Examination Survey 
(NHANES III). Metabolic syndrome is a lifestyle disease i.e., linked to 
increased intake of high-calorie diet, low-fiber foods and physical inactivity 
that led to increased prevalence in developing countries as well. The overall 
prevalence of cardio-metabolic syndrome in India is estimated to be ranging 
from 11% to 41%
5
. 
 A study conducted among urban locale of Eastern India in 1178 subjects 
found that the prevalence of metabolic syndrome was notably higher in females 
(42.3%) than in males (24.9%)
5
. Further, a study conducted among an urban 
Indian population to estimate the prevalence of metabolic syndrome was found 
to be 19.52%
6
. A South Indian study had shown a prevalence of age and gender 
adjusted metabolic syndrome as 73.3%
7
.  Metabolic syndrome is a complex 
web of metabolic factors, and in turn been associated with a 2-fold increased 
risk of cardiovascular disease. In the same study, it was also found that the 
factors contributing to increased risk of metabolic syndrome were old age, 
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female gender, middle-to-high socioeconomic status, inadequate fruit intake, 
obesity and hypercholesterolemia
5
. Simple life style modifications particularly 
at the preface of the syndrome like body weight reduction, habitual exercise, 
diet modification with low-calorie diet, high-fiber foods, would decrease the 
risk of CVD and diabetes mellitus.  
 The annual direct healthcare cost for diabetes and its associated diseases 
worldwide of age 20 to 79 years is estimated to be around 286 billion dollars or 
even more. And it is predicted that this figure would rise to 396 billion dollars 
by 2025 accounting 13% - 40% of global health care budget due to perpetual 
inflation of prevalence
8
. 
 There is no well clear cut-off point in treating metabolic syndrome, as of 
now, individual components are treated in addition to the risk factors of the 
patients and moreover, no single drug is available to treat all the individual 
components of the syndrome altogether. On the other hand, Momordica 
charantia (bitter gourd) tends to possess anti-diabetic, anti-hypertensive, 
hypolipidemic and anti-inflammatory properties individually as a sole agent.  
 With this background, our study aimed to study the effectiveness of 
Momordica charantia, as a mono-therapy for metabolic syndrome. In addition 
our study also aimed at understanding the biological basis of the effect of 
Momordica charantia in the treatment of metabolic syndrome. 
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AIMS AND OBJECTIVES: 
AIM OF THE STUDY: 
 To study the biological basis of the effectiveness of Momordica 
charantia in metabolic syndrome  
PRIMARY OBJECTIVES: 
 To evaluate the effects of Momordica charantia on Lipid 
peroxidation derived aldehydes and superoxide dismutase (markers 
of oxidative stress) in the fructose diet induced metabolic syndrome 
rat model. 
 To evaluate the effects of Momordica charantia on Pro-
inflammatory state (NF-κB) in the fructose diet induced metabolic 
syndrome rat model. 
SECONDARY OBJECTIVE: 
 To evaluate the effects of Momordica charantia on metabolic 
parameters, histopathology of heart and liver in the fructose diet 
induced metabolic syndrome rat model. 
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REVIEW OF LITERATURE: 
METABOLIC SYNDROME: 
  In 1700 it was JB Morgagni who found that there was a web between 
hypertension, visceral obesity, atherosclerosis, hyperuricemia and obstructive 
sleep apnoea
9
. In 1981, Hanefield and Leonhardt were the first to use the term 
metabolic syndrome
10
. Many studies impart the existence of correlation 
between metabolic syndrome and cardiovascular disease.  
 The present concept of metabolic syndrome came when Reaven 
intended that this disease included many entities
11
. Originally, obesity was not 
considered as one of the elements of the syndrome, later central obesity was 
confessed as the most cardinal factor of metabolic syndrome
4
. 
  In 1998, it was World Health Organization (WHO)
12 
which  initiated 
the certainty to implement strategies for the prevention of non-communicable 
diseases that included metabolic syndrome. It is conventionally defined as a 
cluster of symptoms with single common underlying pathology, but factual 
pathology of metabolic syndrome is not yet fully understood so far.   
Diagnosis of Metabolic syndrome:   
World Health Organization (WHO)
12
: 
 By definition, metabolic syndrome is diagnosed by the presence of 
diabetic or impaired glucose tolerance along with any 2 of the following: 
1. BMI >30kg/m
2 
or Waist-to-hip ratio >0.90 in men or >0.80 in women.
 
2. Serum triglycerides ≥ 150 mg/dl in both men and women or HDL 
cholesterol <35 mg/dl in men and <39 mg/dl in women.
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3. Blood pressure ≥ 140/90 mm Hg. 
4. Excretion of albumin in urine >20 mg/min or Ratio of albumin to creatinine 
≥ 30mg/g. 
International Diabetes Federation (IDF)
13
: 
If BMI is found to be >30kg/m², then it is not desired to measure the waist 
circumference and that will implicit central obesity along with any 2 of the 
following: 
1. Triglycerides: >150 mg/dl, or on management for this lipid abnormality. 
2. HDL cholesterol: < 40 mg/dl in males, < 50 mg/dl in females, or on 
treatment for this lipid abnormality. 
3. Blood pressure: >130/85 mmHg, or on therapy for hypertension. 
4. Fasting plasma glucose: >100 mg/dl, or on treatment for diabetes.  
National Cholesterol Education Program (NCEP) Adult Treatment Panel 
III (ATP III)
14
: 
According to its guidelines, diagnosis of metabolic syndrome must have three 
or more of the following: 
1. Waist circumference >102 cm in men and >88 cm in women. 
2. Serum triglycerides ≥ 150 mg/dl or on specific medication. 
3. Blood pressure ≥ 130/85 mmHg or on specific medication. 
4. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific 
medication. 
5. Fasting plasma glucose ≥ 100 mg/dl or on specific medication. 
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PATHOPHYSIOLOGY OF METABOLIC SYNDROME
15
: 
  Central obesity is a key element of metabolic syndrome, found to be 
certainly affiliated to insulin resistance
16,17
. However, the visceral fat 
contributes the total body fat in lean men by only 10% while it is almost 15% 
in obese
18
. Being established that visceral adipocytes are more lipolytically 
active i.e.,converted into free fatty acid compared to subcutaneous adipocytes 
in vitro, these fatty acids are also transported into the portal vein and are 
delivered directly to the liver thereby exposing the liver to more fatty acids
19
. 
 On the other hand, data from a study on isotope tracers for evaluation of 
visceral fat metabolism entrenched that the total free fatty acids delivered to 
liver and skeletal muscle was about 20% and 15% respectively to these organs 
which are derived from lipolysis of the visceral fat, thereby signifying the 
correlation between raised visceral fat and the metabolic complications of 
obesity
20
. 
  The complete perceptive concerning the mechanism of insulin 
resistance is so far not well established. Insulin resistance will initially be 
evident as postprandial hyperinsulinemia, later by fasting hyperinsulinemia, 
and eventually, as hyperglycemia. Initial hyperinsulinemia is owing to elevated 
glucose and FFAs that in turn is responsible for an increase in insulin secretion 
from the pancreas. 
 It is by the action of hormone-sensitive lipoprotein lipase, plasma free 
fatty acids (FFAs) are primarily derived from the adipose stores. Affluence of 
FFAs occurs as a sequel of an increase in adipose tissue mass. Insulin, the 
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regulator of lipid metabolism acts by inhibiting the lipolysis. Development of 
insulin resistance enhances lipolysis, to bring in excess FFAs, paradoxically 
inhibiting the anti-lipolytic activity of insulin
21
. High levels of FFAs also 
accord to and intensify the insulin resistance. In addition, unduly raised FFAs 
impair insulin mediated glucose uptake and gets accumulated as triglycerides 
in skeletal & cardiac muscle, which in turn worsens the insulin resistance
22,23
. 
It is evident that in the myocytes, the metabolites of FFA (long chain 
fatty acyl CoA and diacylglycerol)
21
 are formed, and they play a role as potent 
allosteric activators of phosphokinase C, serine and threonine kinase. 
Occurrence of phosphorylation of serine threonine sites on the Insulin receptor 
substrate 1-kinase (IRS1), leads on to decrease in phophoinositol 3-kinase
24,25,26 
causing decrease in translocation of GLUT-4 from cytoplasm to cell 
membrane, which being an essential requisite for transport of glucose. There is 
surplus glucose production by the liver owing to impaired insulin sensitivity in 
the muscle. There is also a coupled decline in formation of glucose to glycogen 
along with augmented lipid accumulation as triglycerides. 
In addition, there is also impaired oxidation of mitochondrial fatty acid 
that contributes to blunting of insulin‟s action. Adding up to that, there is also 
higher yield of reactive oxygen species, which in turn will activate the pro-
inflammatory nuclear factor kappa B pathway (NF-κB)27, thereby will foster 
insulin resistance [Image-1]. 
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Image-1: Cellular mechanisms for fatty acid-induced insulin resistance
15
 
 
 
 Cholesterol disturbances explicitly hypertriglyceridemia and reduced 
HDL levels are considered as the exceptional markers of insulin resistance. 
FFAs are directed towards the liver, which on reaching it, increases the 
formation of VLDL rich in Apo-B. 
 Surplus triglycerides modify the composition and metabolism of both 
HDL & LDL, with a high proportion of small, dense molecules
28
 [Image 2]. 
These small dense LDL are considered more atherogenic and lethal to the 
endothelium as they can transit through the basement membrane of the 
endothelium and clasp the glycosaminoglycans, making them more vulnerable 
to oxidation and get accumulated in monocyte-derived macrophages.  
 9 
 
Image-2: Schematic representation of dyslipidemia of metabolic syndrome
28
 
 
 
 Hypertension occurs as a result of enhancement of sympathetic nervous 
system activity and sodium reabsorption due to hyperinsulinemia. 
Conventionally, insulin is a vasodilator but that property is lost in the locale of 
insulin resistance
29 
but with preserved renal sodium reabsorption
30
 enhancing 
occurrence of hypertension. Insulin resistance impairs the phophoinositol 3-
kinase signaling accounting for the discrepancy between endothelial nitric 
oxide and endothelin-1 production. 
 The other well established mechanism behind insulin resistance causing 
hypertension is due to increase in free fatty acids that by nature are 
vasoconstrictors
31
. 
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Image-3: Patho-physiology of Metabolic Syndrome
20 
 
  
 The macrophages also produce pro-inflammatory cytokines (adipokines) 
like Interleukins-1, 6, 18 (IL-6, IL-1, IL-18), C-reactive protein (CRP) and 
Tumor Necrosis Factor-α (TNF- α). Adipokines i.e., TNFα suppresses insulin 
signalling
32
; IL-6 increases inflammation directly or by stimulating hepatic 
CRP production
33
; IL-8 activates neutrophils and is chemotactic for all kinin 
migratory immune cells
34
. On the other hand, an anti-inflammatory cytokine 
adiponectin
35
can enhance the insulin sensitivity and tend to inhibit 
gluconeogenesis in the liver, increases glucose transport & fatty acid oxidation 
in the muscle, produced by the adipocytes, is reduced in metabolic syndrome
36
. 
 Prothrombotic state occurs as a result of cytokines and FFAs mediated 
increased production of fibrinogen from the liver and plasminogen activator 
inhibitor-1 (PAI-1) from the adipocytes [Image-3]. 
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Oxidative stress and Metabolic syndrome: 
 Oxidative stress is mediated by the production of reactive oxygen 
species (ROS) and lipid peroxidation derived aldehydes (LDA). 
Lipid peroxidation: 
 Oxidative stress, in any chronic inflammatory disease serves as a trigger 
for the production of reactive oxygen species (ROS) and aldehydes
37
 [Image-4] 
that includes, 
 Acrolein 
 Malondialdehyde (MDA) 
 4-hydroxy-2-hexenal (9HHE) 
 4-hydroxy-2-nonenal (HNE)  
With existence of vicious cycle between ROS and aldehydes, MDA is an end-
product of non-enzymatic PUFA oxidative degradation. 
Image-4: Obesity-lipid peroxidation vicious circle
37
 
 
                                                  
 
 
 
 
 
OBESITY 
[Accumulated fat] 
Pro-inflammation Oxidative stress 
Lipid peroxidation 
↑ ROS Production 
↓ Antioxidant 
↑ Cytokines 
↑ Macrophages 
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Lipid peroxidation and Insulin resistance: 
The vicious cycle between ROS and aldehydes would lead to carbonyl 
stress, which by its action on various organs like muscle, adipose tissue, 
pancreas and insulin peptide lead to decreased production of insulin. The 
proposed mechanism for insulin deficiency is destruction of the beta cells of 
pancreas by the activation of apoptotic signal by lipid peroxidation 
byproducts
38
. Another mechanism is direct adduction of peroxidation 
byproducts to several vulnerable aminoacids in insulin polypeptide
39
. 
Lipid peroxidation and Obesity
40
: 
 Accumulation of 4-hydroxy-2-nonenal (HNE) as result of lipid 
peroxidation occurs not only in adipose tissue, but also in skeletal muscles.On 
the other hand, there is a selective increase in ROS levels in white adipose 
tissue that could blunt the expression of antioxidant enzymes including 
superoxide dismutase. 
Superoxide dismutase (SOD): 
 SOD is an enzyme that catalyzes the conversion of superoxide ions to 
O2 and H2O2, thereby preventing the cells from oxidative damage by 
superoxide ions. Though H2O2 is also prone to cause damage to the cells, it is 
not to the extent produced by superoxide ions. There exits numerous forms of 
SOD and they are classified based their cofactors usually, the metals like 
copper/zinc, iron/manganese and nickel to which they attach to as Cu/Zn type, 
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Fe/Mn type, and the Ni type, respectively. A reduction in SOD activity is 
indicative of oxidative stress. The probable reasons for the reduction would be 
due to either glycosylation of SOD and/or loss of a cofactor required for SOD 
activity
41
. 
Pro-inflammation and Metabolic syndrome: 
 Pro-inflammation is a state characterized by increased expression of the 
pro-inflammatory marker NF-κB. NF-κB is a pro-inflammatory mediator found 
to play a key role in ordinance to immune, inflammatory, stress responses, and 
also in apoptosis. NF-κB is a combination of five proteins, expressed as 
subunits p50, p52, p65, c-Rel, and RelB
42
. Various external stimuli, like 
pathogens, allergens, and mediators of injury, infection and inflammation such 
as oxidants, chemokines, cytokines, and growth factors trigger the various 
cellular signals for activating the pro-inflammatory transcription mediator NF-
κB, as it is redox stress sensitive. This NF-κB translocates into the nucleus 
upon phosphorylation and will bind to the κB sequence of the DNA, in turn 
transcribing a wide variety of genes coded for oxidants, chemokines, cytokines, 
and growth factors
43,44
. 
Lipid derived aldehydes in NFκB mediated cell signaling: 
 Increased ROS levels activates NF-κB apart from numerous redox-
sensitive transcription factors like, AP1,ERF2, NFAT, ATF2 and CREB and 
this has been implicated in various studies on inflammatory diseases
43
.Thus 
LDAs from ROS play a lead role in activating the factors of transcription 
through downstream activation of protein kinase signaling cascade. 
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Image-5: Lipid derived aldehydes-induced inflammatory signaling
45 
 
                           
 
 
 
 
 
 
 
 
 
 This in due course could lead to progression and establishment of the 
chronic inflammatory diseases. Many studies have proven the efficacy of 
antioxidants in the treatment of infections, autoimmune disorders, allergic 
complications, metabolic disorders and degenerative diseases
44,45
 [Image-5]. 
STANDARD TREATMENT OF METABOLIC SYNDROME: 
 The goal to be achieved in treating a patient with metabolic syndrome is 
that all the components are treated individually in accordance with the risk 
ROS 
Lipid derived aldehydes 
Protein kinase signaling cascade 
NF-κB 
Cytokines, Chemokines,  
Growth factors, Leukotrienes,  
Other inflammatory mediators 
 
Inflammation 
External stimuli 
Cell membrane 
Mitochondria NADPH oxidase 
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factors associated. IDF‟s recommendation in the treatment of metabolic 
syndrome is primarily aimed at life style modification. That includes; 
 Moderate restriction of calorie [5-10% weight loss during first year] 
 Moderately increased physical activity of 30 minutes daily 
            The secondary intervention is mainly for those who don‟t respond to 
life style modification, and is aimed at treating the individual components of 
the disease. The recommendation by IDF includes therapy of, 
 Insulin resistance and Hyperglycemia  
 Elevated blood pressure 
 Atherogenic dyslipidemia 
Treatment of insulin resistance and hyperglycemia: 
METFORMIN: 
 Biguanides and Thiazolidinediones are insulin sensitizers used in the 
treatment of hyperglycemia and insulin resistance associated with metabolic 
syndrome. Metformin is the commonly used first line oral hypoglycemic 
biguanide for management of obesity and insulin resistance in metabolic 
syndrome. The action of metformin is that it phosphorylates and activates 
adenosine monophosphate-activated protein kinase (AMPK). Activated AMPK 
plays the function of oxidizing fatty acid, increasing uptake of glucose, and 
stimulating non-oxidative metabolism, thereby reducing lipogenesis and 
gluconeogenesis. As a result, there will be profound increase in skeletal muscle 
glycogen storage, reduced hepatic glucose production resulting in 
hypoglycemic action. The reduction of lipogenesis has been implicated as a 
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major contribution for the weight loss produced by metformin. It in addition 
has the potency to reduce the triglycerides, and LDL by about 8% to 15% and 
discreetly increases high-density lipoprotein (HDL) level by 2%
46
.Various 
studies had proven the effectiveness of metformin in treating obese diabetics. 
In the fructose diet induced model of metabolic syndrome represents obese 
diabetics, a dose of 180 mg/kg/day
47
 in rats will effectively produce weight loss 
and hypoglycemia. 
Treatment of elevated blood pressure: 
TELMISARTAN: 
The elevated blood pressure in metabolic syndrome is treated either by 
ACE [Angiotensin converting enzyme] inhibitors or ARB [Angiotensin II 
receptor blocker] as these two groups of drugs are considered as first choice 
according to IDF [International Diabetes Federation]. Captopril Prevention 
Project (CAPPP)
48
,Heart Outcomes Prevention Evaluation (HOPE)
49
 trial and 
Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication 
(DREAM) trial had shown that there was significant mortality benefit with 
ACEIs. But in addition, ARBs have a role of causing significant regression of 
left ventricular hypertrophy as proven by Losartan Intervention for Endpoint 
Reduction (LIFE)
50 
and Valsartan Antihypertensive Long-term Use Evaluation 
(VALUE)
51
 trials. 
 Telmisartan is a non-peptide benzimidazole Angiotensin II receptor 
blocker. The mechanism of its antihypertensive action is that it selectively 
antagonizes the binding of angiotensin II to AT1 receptor subtype. Angiotensin 
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II is a pressor agent, the key agent in causing vasoconstriction and production 
of aldosterone causing sodium retention and also increasing MMPs and causing 
cardiac hypertrophy and remodeling. Few other studies had proven the 
effectiveness of telmisartan in improving cardio-metabolic functions, and also 
as the anti-oxidant and anti-inflammatory activity probably relating to its 
PPAR-γ partial agonistic activity52. A study on hypertensive animal model had 
shown that even a low dose [3 mg/kg/day] of telmisartan could significantly 
reduce blood pressure
53
.  
Treatment of atherogenic dyslipidemia: 
ROSUVASTATIN: 
Atherogenic dyslipidemia associated with metabolic syndrome is treated 
by either statins or fibrates. Statins are inhibitors of HMG-CoA [3-hydroxy-3-
methylglutaryl- coenzyme A] reductase, the chief enzyme of mevalonate, the 
precursor for synthesis of cholesterol and other non-steroidal iso-prenoid 
compounds. In addition, statins reduces the intracellular cholesterol by 
inducing protease activity responsible for splitting off the endoplasmic 
reticulum attached sterol regulatory element binding proteins (SREBPs). Later, 
these SREBPs are internalized into the nucleus, augmenting the LDL receptor 
gene expression. On the other hand, reduced hepatic cholesterol levels would 
upregulate the LDL receptors in the liver, the primary determinant of 
precursors of LDL (IDL, VLDL) and also circulating LDL, all of which are 
reduced
54
. It has been studied that, in comparison to other statins, rosuvastatin 
has increased binding sites to the HMG-CoA reductase making it a potent 
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inhibitor of the enzyme with great therapeutic efficacy
55
. Randomized, placebo 
controlled JUPITER (Justification for Use of statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin), had revealed the pleotropic effects 
of the drug. An earlier research stated that even low dose of 2mg/kg/day was 
proven to be sufficient to establish hypolipidemic activity in animal models
56
. 
MOMORDICA CHARANTIA: 
 Momordica charantia traditionally called as bitter melon or bitter gourd 
is a climber belonging to the family Cucurbitaceae. It is distributed widely in 
India, Malaysia, China, East Africa and South America. By Latin, Momordica 
meaning “to bite” been named in reference to the jagged edges of the leaf, i.e., 
like bitten leaves
57
. M.charantia has an array of chemicals which are 
biologically active, that includes saponins, triterpens, flavonoids, steroids, 
proteins, alkaloids, phenolic compounds and lipids. It is also rich in beta-
carotene and vitamins A, C, E, B1, B2, B3 and B9, as well as the minerals 
potassium, iron, and phosphorus. The caloric values for fruit, leaf and seed are 
241.6, 213.26, and 176.61 Kcal/100 g respectively
58
. Fruits of M.charantia are 
proved to be useful in the treatment of diabetes, asthma, malaria, gout, 
helminthiasis, abdominal colic, constipation, cough, leprosy, skin diseases, and 
also as ulcer healing agent
59,60
. Leaves found to cure menorrhagia, constipation, 
malaria, abdominal colic, measles, hepatitis, worm infestation, and are even 
used topically for wounds and infections
61
. Seeds are used in the treatment of 
peptic ulcer, diabetes, and hypercholesterolemia
62
. Roots found to have role in 
the treatment of syphilis, rheumatism, ulcers and septic swellings
59
. 
 19 
 
Thus the medicinal properties of the whole plant are well established over 
years. 
Fruits of M.charantia were proven to have anti-obesity, anti-diabetic, 
anti- hypertensive, hypolipidemic and anti-inflammatory properties by various 
studies. 
Anti-obesity activity: 
 Adipogenesis is maturation of preadipocytes to adipocytes; and 
enlargement of adipocytes with amplification in cell number plays a vital role 
in obesity. It is also important in pathogenesis of type-2 diabetes mellitus and 
insulin resistance
63
. Peroxisome proliferator-activated receptor γ (PPARγ) is 
considered as the "master regulator of adipogenesis"
64,65
. Other transcription 
factors found to be involved in adipogenesis include the SREBP-1c and 
CCAAT/enhancer binding proteins (C/EBPα, C/EBPβ and C/EBPδ)66,67,68. 
Likewise, lipolysis from breakdown of adipose triacylglycerols into glycerol 
and non-esterified fatty acids involves not only the enzymes TAG hydrolases 
and lipases, but also lipid-droplet coating protein named perilipin
69,70
. In 
addition to transcription factors, adipocytokines secreted by adipocyte also play 
a key role in preadipocyte differentiation.                                                 
 M.charantia has several active chemicals that include a steroid 
glycoside charantin, a 166 residue insulin mimetic peptide called plant insulin 
or polypeptide "p"
71
, glycosides such as mormordin, polyphenols, quercetin 
and gallic acids
72,73,74
, vitamin C, carotenoids, and flavanoids. Studies have 
shown that, quercetin has been proven to persuade apoptosis and hamper 
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adipogenesis in 3T3-L1 mouse adipocytes
75,76
, on the other hand gallic acid in 
culture is known to augment the number of both early and late apoptotic 3T3-
L1 cells
77 
by means of loss of mitochondrial membrane potential. Recent 
studies have shown that bitter melon juice also inhibits differentiation by 
adipocyte by reducing mRNA gene expression of PPARγ, SREBP and perilipin 
and also by increasing lipolysis
78
. 
 A cue enzyme of lipogenesis, Glycerol-3-phosphate dehydrogenase 
(G3PDH), is responsible for directing the intermediates of glycolysis towards 
triacylglycerol synthesis
79
. A study had proven that anti-adiposity effect of rats 
treated with bitter melon was due to reduced activity of G3PDH and TAG 
content, thereby accounting for the suppression of lipogenesis in adipose 
tissue
80
. 
Triterpenoids of bitter melon have shown to increase adenosine 5 
monophosphate kinase (AMPK) facilitating the cellular glucose uptake and 
oxidation of fatty acid
81
[Image-6]. The adipocytes deliver their contents to 
preserve balance of energy and this increased oxidation fatty acid will 
eventually lead on to weight loss
82
. 
Anti-diabetic activity: 
 Charantin and momordicin are the two key chemicals of therapeutic 
value extracted from M.charantia. Charantin is an quinolizidine alkaloid, 
steroidal saponin having insulin-like properties and is accountable for the 
bitterness of fruit. 
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 Studies have shown that M.charantia, found to inhibit the two key 
gluconeogenic enzymes glucose-6-phosphatase and fructose 1, 6-
diphosphatase, while stimulates glucose-6-phosphatase dehydrogenase of HMP 
pathway
83,84,85,86
. In addition it also inhibits hexokinase enzyme
87
. 
 Other possible mechanism for the hypoglycemic action established by 
various studies is that M.charantia found to possess insulin secretagogue 
action
88
. A study done by incubating either insulin or the Momordica juice with 
a PI3K inhibitor, wortmannin had shown to inhibite 
3
H-deoxyglucose by L6 
myotubes markedly in comparison to the glucose uptake from either insulin or 
the juice alone indicative of insulin like action and in addition, it can also 
galvanize the uptake of amino acid into the skeletal muscle cells as with 
insulin. Hence it is proven to stimulate peripheral and skeletal muscle glucose 
utilisation
89
. 
Image-6:Illustration of the activation of AMPK by Bitter-melon triterpenoids
81
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 Regular intake of juice of M.charantia fruit for 10 weeks is shown to 
reduce the absorption of sodium and potassium dependent 14-Carbon D-
glucose in brush border of jejunum. Another study proved that 
M.charantia alleviated pancreatic damage and thereby helpful in restoration of 
islet beta cells and their function. M.charantia fruit extract increases the 
number of β-cells90 in the diabetic treated rats, but has no role in improving the 
alpha cells and delta cells
91
. 
Hypolipidemic activity: 
 The family of nuclear fatty acid receptors including PPARs has been 
implicated to play a vital role in numerous metabolic diseases related to 
obesity. There are three PPAR subtypes namely α, γ and δ each of which are 
found to have distinctive expression and regulate various lipoprotein 
components. These receptors are also unique in regulation of homeostasis of 
lipid with reference to the specific tissue need. 
 PPAR-α is found to be involved in regulation of genes pertaining to 
hepatic fatty acid uptake, β-oxidation and ω-oxidation. PPAR α, in addition 
also down-regulates apolipoprotein C-III, a protein that inhibits hydrolysis of 
triglycerides by lipoprotein lipase (LPL). Thus, lipid-lowering effect of PPAR 
α ligands is attributed to these actions92. 
 PPAR γ is unique with their prominent expression in adipocytes and it is 
involved in the differentiation of adipocyte from fibroblasts
93
. Studies based on 
the activity of PPAR γ in lipid-laden macrophages have shown that its activity 
will induce scavenger receptor CD36 causing accumulation of lipid
94,95
. The 
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efflux of cholesterol is also promoted by inducing a cascade of transcriptional 
events through the sterol nuclear receptor LXRα and ABCA1 for HDL 
cholesterol-mediated reverse transport
96,97,98,99
.  
 PPAR δ is rich in myocytes and a ligand to this receptor is proficient in 
regulating the genes of malonyl-CoA decarboxylase, CPT1, and UCP3 that are 
important for fatty acid catabolism thus increasing the fatty acid oxidation in 
myocytes
100
. 
  Overall, PPAR α, δ activation induces the catabolism of fatty acid both 
in muscle and liver and PPARγ is considered essential for both storage as well 
as differentiation of the adipocytes. VLDL and ox-LDL are taken up by the 
macrophages present in the vessel wall and the cholesterol that is in excess will 
be eventually be effluxed through the HDL pathway. Momordin significantly 
increased the PPARδ production by up regulating the expression of PPARδ 
mRNA and promoter activity
92
, thereby increased HDL and decreased LDL
101
 
[Image-7]. 
Bitter melon also improves lipid profiles
82
 by, 
▪ Decreasing the secretion of apolipoprotein B (Apo B) the primary 
lipoprotein of LDL by liver. 
▪ Decreasing the apolipoprotein C- III expression, the protein found in 
VLDL which turns into LDL. 
▪ Increasing the expression of apolipoprotein A-1 (ApoA1) the major 
protein component of HDL. 
▪ Decreasing the cellular triglyceride content. 
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Image-7: Illustration of PPAR-γ/δ activity of Charantin101 
 
 
 
Anti-hypertensive activity: 
 The hypotensive effect is well established in many studies, one of the 
probable mechanisms is mainly by blocking peripheral α and/or β 
adrenoceptors in blood vessels and cardiac muscle
102
. It is also evident by 
intake of okinawan vegetables (yellow-green vegetables) rich in potassium 
would cause natriuresis and which in turn lead on to increased blood pressure. 
Momordica is one of those okinawan vegetables, and it is rich in potassium 
296mg/100gms against 5mg of sodium
103
. 
There was a study done recently that demonstrated the existence of 
antihypertensive peptide VY-7 from bitter melon seed protein possessing ACE 
inhibitor property
104
. 
 
CHARANTIN 
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Anti-inflammatory activity: 
 Bitter melon has been shown to reduce the levels of PG E
2
, IL-1, IL-6, 
IL-7, and TNFlevels in addition to increasing the expression of PPAR105. A 
study hypothesized to prove the anti-inflammatory activity of M.charantia 
found that the active compounds charantosides-C and momordicoside G have 
the maximum anti-inflammatory activity proven by the inhibitory effects on 
NF-κB expression in HepG2 cells106. 
 There are no studies reported in literature on the effects of M.charanti 
ain metabolic syndrome, which is a constellation of the various cardio-
metabolic manifestations, the activity of M.charantia in the individual 
components having been proven by different preclinical studies. In addition, 
metabolic syndrome also is a pro-inflammatory state with oxidative stress and 
the effectiveness of M.charantia in these has not been studied till date. A 
preclinical animal study was therefore designed to assess the effects of the 
fresh juice preparation of M.charantia in the metabolic syndrome animal model 
which included an assessment of the changes in the pro-inflammatory state 
marked by the serum NF-κB and the change in oxidative stress with LDA and 
SOD as markers. 
MODELS OF METABOLIC SYNDROME
107
: 
 There are various validated animal models of metabolic syndrome. Rats 
are considered as the most common laboratory experimental animal for 
studying the metabolic turnover in the body. It is also convenient to investigate 
the adaptive changes to various morphological, functional, and biochemical 
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factors using rats. There are numerous models of metabolic syndrome been 
established so far which are; 
▪ Dietary models of metabolic syndrome 
▪ Genetic models of metabolic syndrome 
▪ Metabolic syndrome induced by pharmacological manipulations 
Dietary models of metabolic syndrome: 
High-carbohydrate diet: 
 Various studies
108-113 
have shown that use of refined carbohydrates like 
HFCS (high fructose corn syrup) and sucrose, are established to cause increase 
in BMI, rise in the level of circulating triglycerides, and development of insulin 
resistance in humans and animals in particular with rats. 
High-fat diet: 
Based on the quantity of fat ingested, the diets are classified into; 
▪  Low-Fat Diets (LFD) -10 % 
▪ High- Fat Diets (HFD) - 30-50 %  
▪ Very High-Fat Diets (VHFD) - more than 50 % 
A research studied the metabolic and molecular effects in rats on high fat diet 
found that the association between obesity, insulin resistance, hepatic steatosis, 
activation of SREBP1c in liver and ingestion of high fat diet
114
. Another study 
states that insulin resistance of rodents fed with high fat diet is similar to 
reduced insulin sensitivity in humans which probably is due to increase in 
triglyceride content in muscles
115
. 
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Combined high-fat and high-carbohydrate diet (HFCD): 
 Increased body mass index is observed with high-fat diet and an 
increase in triglyceride levels are observed mainly in high fructose-fed rats
116
. 
The combination of high-cholesterol and high-fructose diet is associated with 
an increase in total cholesterol, reduction in HDL and doubling of liver‟s 
weight
117 
and importantly the rapid damage to the cardiac tissue produced 
(within 4 weeks), which guides a detailed study of morphological, biochemical 
and functional features of the pathogenesis of cardiovascular changes, in 
addition of the metabolic changes
118,119
. 
Diet with a high content of NaCl and fructose: 
 Combining NaCl with fructose leads to the development of hypertension 
in rats, but they can also develop metabolic syndrome. Use of high content of 
NaCl (8% NaCl) for two weeks is associated with hypertension with no 
substantial body weight changes
14
. The rise in body mass and also the 
associated metabolic changes are achieved by the addition of high-fructose 
diets (60 %) 
120,121
. 
Diets Imitating Human Dietary Habits: 
 The result following intake of “Western diet” rich in saturated fatty 
acids, cholesterol, sugar and NaCl in rats have affected glucose homeostasis, 
lipid profile and adipocyte hormones
122
. Usage of tasty food in Wistar rats 
causes increased intake of food, proliferation of brown adipose tissue, rise in 
temperature and elevated plasma leptin levels
123
. Similarly intake of so-called 
cafeteria diets (containing crushed biscuits, waffles, snacks, etc.) causes 
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obesity, deteriorated glucose tolerance, decreased insulin sensitivity and 
proinflammatory status thus making it as an effective model of a metabolic 
syndrome
124
. 
Prenatal dietary manipulations: 
 Restriction of diet prenatally leads to fetal retardation of both endocrine 
and metabolic status
124
. It is also found that reduction in protein intake during 
pregnancy leads to decrease in beta-cell proliferation and reduction in the size 
of islets of Langerhans
125,126
. Rats fed with high fat diet during pregnancy result 
in fetal insulin resistance, abnormal cholesterol metabolism and high blood 
pressure
127,128
.  
Genetic models: 
Zucker rats (ZDF) Obese rats: 
 These rats are widely studied and are considered as the one of the best 
models of metabolic syndrome. They possess a mutation (fa/fa) along with 
leptin receptor deficiency
129
. They model is characterized by hyperphagia, 
disrupted glucose tolerance, insulin resistance, hyperinsulinemia, hypertension, 
dyslipidemia, endothelial dysfunction, pro-inflammatory and oxidative status 
along with increased expression of ghrelin
130,131,132
. 
SHR (Spontaneously Hypertensive Rats): 
 Other genetic model of metabolic syndrome established is obese 
spontaneously hypertensive rats. Mature rats of this model also present with 
obesity, hypertriglyceridemia and hypertension. 
 
 29 
 
LCR (Low-capacity runners): 
 This model has low aerobic capacity, characterized by central obesity, 
hyperinsulinemia, insulin resistance, hypertension, endothelial dysfunction, 
hypertriglyceridemia and elevated plasma fatty acids
133
. 
Other models: 
▪ db/dbmouse
134
 
▪ KKAy mice
135
 
▪ ob/obmice
136
 
▪ Wistar Ottawa Karlsburg W
137
 
▪ DahlS.Z-Lepr
fa
/Lepr
fa138
 
▪ Otsuka Long-Evans Tokushima Fatty
139
 
▪ Goto-Kakizaki
140
 
Pharmacological manipulation: 
MSG-induced SHR
141-144
: 
 MSG-induced SHR (Monosodium Glutamate-Induced Spontaneously 
Hypertensive Rat) induces cardiovascular changes that include raised BP, 
reduced sensibility of baroreflex, and increased balance in sympatho-vagal 
activity. 
Streptozotocin administration
145
: 
 Streptozotocin, even with a single application would produce beta-cell 
damage, thus insulin dependent diabetes mellitus could be achieved. 
Preferred model for metabolic syndrome: 
▪ Fructose diet induced model is the preferred model, as it could 
produce all the entities of metabolic syndrome.  
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▪ High fat diet model could produce all entities except hypertension. 
▪ Combined high carbohydrate and high fat diet model usually had a 
rapid onset and deterioration of cardiovascular morphology, so not 
suitable for studying metabolic parameters. 
▪ Combined NaCl and fructose was preferred as a hypertensive 
model over metabolic syndrome. 
▪ Genetic models are expensive. 
▪ Models with pharmacological manipulations would not undergo a 
natural course of disease progression and development. 
Thus dietary fructose model was preferred for the study. 
 
 Fructose, one of the natural sugars is commonly used as sweetener. 
Fructose also serves as a main constituent of natural fruits and honey, packaged 
foods and soft drinks
146
.Fructose diet in rat is found to produce the effects best 
at 60% and 66%, but time taken for induction of metabolic syndrome is longer 
with 60% fructose (8-12 weeks)
147,148,149
 compared to 66% fructose (4-6 
weeks)
150,151,152
. 
Fructose consumption and Obesity: 
 The probable mechanism behind the development of obesity with 
fructose is suppression of leptin levels
153
. Leptin is the hormone regulating the 
sensation of satiety, thus leading to increased caloric intake and weight gain. 
Few other studies have shown an increase in plasma leptin levels
154
, with leptin 
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resistance, explaining the direct relationship between consumption of high 
fructose diet and obesity. 
Fructose consumption and Insulin resistance: 
 Fructokinase, an enzyme involved in the phosphorylation of fructose to 
fructose-1-phosphate with ATP as donor of phosphate, but in contrast to 
glucokinase, has no negative feedback, therefore resulting in depletion of ATP 
along with accumulation of the phosphorylated substrate. As a consequence, 
there will be increased conversion of nucleotides to uric acid, leading to 
hyperuricemia
155
. It was believed that increase in uric acid would lead to 
insulin resistance
147,156
. The uric acid also impairs endothelial function 
i.e.,nitric oxide (NO) induced vasodilation, nitric oxide that is essential to 
enhance glucose uptake into the tissues by insulin
157
. 
Fructose consumption and Hyperlipidemia: 
 In normal circumstances, fructose being a reducing agent, undergoes a 
process called fructation so that serum lipids and proteins are prevented from 
being damaged by fructose. But in case of excessive fructose in the 
bloodstream, glycation damages vulnerable proteins, and these proteins further 
undergo oxidative damage producing advanced glycation end products 
(AGEs)
158
. LDL being susceptible to glycation, and once glycated they are 
poorly recognized by lipoprotein and scavenging receptors
159
. The changes in 
energy metabolism noted with development of obesity found to be linked to 
hypertriglyceridemia
160
. 
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Fructose Consumption and Hypertension [Image-8]: 
 Fructose acts in such a way that diet with 48–57% fructose or 10% 
fructose in drinking water in rats being sufficient to induce hypertension
161
. 
Hyperinsulinemia as compensatory to insulin resistance is considered as the 
predisposing factor for development of hypertension.  
 There are numerous mechanism postulated for the development of 
hypertension that includes; 
▪ Sympathetic nervous system (SNS) activation causing increase in 
circulating catecholamines
162,163
. 
▪ Activation of Renin Angiotensin Aldosterone System leading to 
rise in Angiotensin II levels
164,165
. 
▪ Enhanced reabsorption of sodium due to increase in activity of 
Na+/H+ exchanger
166
. 
▪ Impaired endothelium dependent relaxation along with increased 
secretion of endothelin-1
167
. 
 
Fructose Consumption and Vascular Dysfunction: 
 The vascular dysfuction caused by fructose is due to insulin resistance, 
which in turn causes blunting of eNOS activity leading to reduced nitric oxide 
(NO) production resulting in impaired endothelium-dependent relaxation
168
. 
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Fructose Consumption and Oxidative Stress: 
 Consumption of fructose leads to the oxidative damage due to 
production of ROS and defective antioxidant defense mechanism
169
. Fructose 
intake also caused lipid peroxidation presenting as increased levels of MDA 
and reduced glutathione (GSH) levels
170
. 
 
Image-8:Proposed mechanism of fructose feeding causing metabolic syndrome
177 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fructose 
Dyslipidemia Oxidative stress ↑ Uric acid ↓ BRA 
Insulin resistance 
Hyperinsulinemia 
↑ Vasoconstriction ↑ RAS ↑ SNS 
↑ Na+ retention Endothelial 
dysfunction 
Hypertension 
 34 
 
Histopathological changes in organs: 
 The organs commonly affected by high fructose diet are liver, heart, 
kidneys, pancreas and blood vessels. 
 Many studies had demonstrated that fructose has the potential tocause 
fatty liver, pathologically, non-alcoholic micro and macrovescicular 
hepatosteatosis in both mice and rat models
171,172,173
. Hearts of the rats fed with 
66% fructose have shown a significant hypertrophy of cardiac muscles along 
with focal myonecrosis and lymphocytic infiltration
174
.  
 While pancreas being demonstrated as one of the prime organs damaged 
by excess intake of fructose, the damage in terms of β-cell destruction was well 
thought-out as the probable reason for hyperglycemia
175
. Few studies also 
established the existence of vascular injury with allusion to increased vessel 
wall reactivity and oxidative stress by fructose
176
. Yet, few other studies also 
demonstrated morphological changes in kidney such as fatty infiltration and 
thickening of glomeruli
177
. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
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MATERIALS AND METHODS: 
 Before the initiation of the study, we obtained the ethical approval from 
Institutional Animal Ethics Committee (IAEC), PSGIMS&R, Coimbatore. 
34 Adult, male Sprague-Dawley rats weighing 150-200g aged 3 months were 
included in our study.  
Animals were randomly allocated into 4 groups; 
 Group I: Treatment group 1 (M.charantia extract-300 mg/kg/day) -(10) 
 Group II: Treatment group 2 (M.charantia extract-600 mg/kg/day)-(10) 
 Group III: Standard treatment group (Metformin-180mg/kg/day + 
Telmisartan-2.5mg/kg/day + Rosuvastatin -2.5mg/kg/day)-(8)  
 Group IV: Normal control-(6) 
 The animals were group housed, 4 rats per cage at a constant ambient 
temperature on a 12 - h light, 12 - h dark cycle. Pellet diet containing 66% 
fructose
177 
made from D- fructose [purchased from Loba chemie laboratories] 
was given to 28 animals and standard rat chow diet to 6 controls and water 
were provided ad libitum out of 34 for 6 weeks.  
 Then serial measurements of body weight, BMI, fasting blood sugar 
were done at the baseline and every week thereafter, whereas noninvasive 
blood pressure, serum lipid profile, LDA, SOD and serum NF-κB were 
assessed at the base line and at the end of 6 weeks (i.e., following 
induction).Then at the end of induction, 28 animals of 3 groups which were fed 
with fructose were provided M.charantia extract-300 mg/kg/day, M.charantia 
extract- 600 mg/kg/day and standard treatment respectively. 
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Image-9: Flow chart of study design 
 
 
 And those animals were provided with standard chow and water ad 
libitum all through the 6 weeks of treatment. Then serial measurements of all 
the parameters were assessed at the end of 6 weeks (i.e., following treatment). 
 Finally, at the end of the study 2 rats from each of the groups were 
sacrificed for histopathological examination of liver and heart to seek for 
pathological changes developed during induction and magnitude of the reversal 
of changes following treatment [Image-9]. 
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Method of blood collection: 
 Tail cut bleeding (tail snip method)
178
 was the method of blood 
collection used in our study. Requirements included the animal, anesthetic 
agent (ether), spirit, cotton, surgical blade and blood sample collection tubes.  
▪ Procedure was performed using anesthetized animal, they were placed in 
the restrainer. The animal was placed on a clean work surface. Removed 
the bedding material or feces from the tail, using skin disinfectant. 
▪ With the help of a fresh scalpel, distal end of the tail of about1-2 mm 
was sniped at an angle of 90
o 
to the surface. 
▪ Gentle pressure was applied proximal to the collection site to occlude 
venous return and for ease collection. 
▪ The blood was collected in a suitable collection device. Gentle digital 
pressure was applied on the wound for 30-45 seconds with clean cotton 
to stop any bleeding. 
▪ The animal was monitored continuously as it was anesthetized, until the 
animal had fully recovered. 
Serum separation: 
 Blood samples were collected from the rats by tail snip method, and 
allowed to clot; later on centrifugation for about 5 minutes at 3,000 rpm was 
done to separate the serum. The serum samples were preserved at -20
o
C for 
estimation of Nuclear Factor Kappa B(NF-κB). 
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Body mass index measurement: 
 The anthropometrical parameter BMI
179 
was determined in our study 
from body weight and body length (nose-to-anus length) using the formula; 
BMI (Body mass index) = body weight (g) / length2 (cm2) 
 
Blood glucose estimation: 
 We followed the method of blood glucose estimation with glucometer, 
according to the Institutional animal care and use committee (IACUC)
180 
standard procedure for glucose monitoring of blood in rats and mice. 
▪ Conscious animal was restrained in a restrainer of appropriate size. 
▪ For better visualization of the veins, the bedding material or feces 
was cleaned off from the tail, using skin disinfectant prior to blood 
collection. 
▪ The lateral tail vein was nicked using a sterile scalpel blade and the 
tail was gently milked. One droplet of blood was placed on a glucose 
test strip and the blood glucose level was read using a glucometer. 
▪ Direct pressure was applied to achieve hemostasis. Following that the 
animal was monitored for 5-10 minutes. 
Non-invasive blood pressure (NIBP): 
 LE 5002, non-invasive blood pressure meter (Panlab-Harvard apparatus) 
was used for measuring the blood pressure in rats. This technique needed a 
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process of adaptation by the animal along with proper placement of cuff and 
transducer on the animal.  
▪ The room or laboratory where the recordings were taken was kept noise 
free. Conscious animal was restrained in a restrainer of appropriate size. 
The animal‟s tail was kept clean so as to improve the contact between 
skin, cuff and the transducer. 
▪ As stressed rat could transmit the muscular tremors to the tail, which 
would hinder the signal captured by the transducer, the animal was 
tamed and kept calm to avoid movements as that could produce artifacts. 
▪ The NIBP instrument was switched on after a working time of 5 minutes 
The cuff was connected to the “CUFF” plug and ensured it was locked 
in place. The pulse transducer was connected to the “TRANSDUCER” 
input. The cuff membrane was checked for spontaneous wrinkles and 
folds (indicative of good positioning). 
▪ The cuff and the transducer were fit simultaneously to the tail of the 
animal. The pressure applied on the tail by the transducer was set 
optimum, as the spring could sufficiently keep it attached to the tail. 
▪ The instrument “GAIN” was adjusted until a proper pulse signal was 
achieved on the display. 
▪ The animal had undergone a process of vasodilatation prior to blood 
pressure recording using a ventilated heater with thermostat between 
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29
o
C and 32
o
C for 20 minutes. Throughout this period the heart rate was 
monitored in the flashing of the “BEAT”. 
▪ After a period of 20 minutes the blood pressure was measured, once the 
pulse level bar reached the “READY” label as “PULSE LEVEL 
READY” on the digital display. 
▪ Once the “START BUTTON” was pressed, the cuff pressure rose to a 
level that could occlude the blood flow and the pulse signal disappears, 
following which the blood pressure starts raising and the end the display 
would show systolic, diastolic, mean arterial pressure (MAP) and pulse 
rate. 
▪ After a short delay, the valve was opened thereby the cuff pressure could 
reduce. The animal studied was then removed from the restrainer and 
monitored for 5-10 minutes. 
ESTIMATION OF LIPID PARAMETERS: 
The lipid parameters estimated using GenX lipid parameters estimation 
kit, manufactured by Proton Biologicals India Pvt. Ltd (Bangalore) were serum 
total cholesterol, triglycerides and HDL (high density lipoprotein) cholesterol. 
The reagents and standards used in the estimation were stored at a temperature 
of 2-8
o
C. 
Serum total cholesterol estimation: 
Principle: Cholesterol,a steroid with secondary hydroxyl group in the C3 
position was estimated by “CHOP/PAP TRINDER‟S METHOD”. 
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Cholesterol ester + H2O                       Cholesterol + Free fatty acids 
Cholesterol ester + O2                          Cholest-4 ene 3-one + H2O2 
H2O2 + Phenol + 4-Aminoantipyrine          Red Quinoneimine Complex+ H2O 
Reagent and its components: 
The reagents provided in the kit include, Cholesterol reagent and Cholesterol 
standard (Conc.200 mg/dl).The components of the reagent were as follows; 
Cholesterol Oxidase 1 KU/L 
Cholesterol Esterase 0.6 KU/L 
Peroxidase 5 KU/L 
4 –Aminoantipyrine 0.5 mmol/L 
Phenol 20 mmol/L 
Phosphate Buffer (PH - 7) 50 mmol/L 
Triton X 100 0.1% 
Activators & Stabilizers  
 
Sample used: Serum 
Procedure: 
▪ The test tubes were arranged in a rack in order as per our need. The test 
tubes were labeled as Blank (B), Cholesterol standard (Conc.200 mg/dl), 
and Test samples (T1, T2 and so on as per the number of samples we 
had). To the Blank (B) test tube 1 ml of Cholesterol reagent alone was 
added. 
CHE 
CHOD 
POD 
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▪ To the Standard (S) test tube 10 µl of Cholesterol standard (Conc.200 
mg/dl) was added following the addition of 1 ml of Cholesterol reagent. 
▪ To the Test (T) test tubes 1 ml of Cholesterol reagent was added and 
later 10 µl of the test serum samples were added in their respective tubes 
promptly in reference to the labeling. 
▪ Caution was taken by to ensure thorough mixing of reagent and the 
samples added. Then, the samples were incubated for 5 minutes at 37
o
C. 
▪ Following incubation the absorbance of the Standard (S), Test (T) was 
read against Blank (B) using the semi-autoanalyzer at 505 nm. 
The total cholesterol was estimated in the semi-autoanalyzer using the formula; 
                                                               ABSORBANCE OF TEST 
   TOTAL CHOLESTEROL =                                                                X 200 
                      (in mg/dl)                      ABSORBANCE OF STANDARD 
 
BIORAD system parameters: 
Reaction mode End point 
Units mg/dl 
Wavelength  505 nm 
Blanking With  Reagent 
Flow Cell Temperature 37
o
C 
Sample Volume 10 µl 
Reagent Volume 1000 µl 
Linearity  1000 
Standard Concentration 200  
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Serum Triglycerides estimation: 
Principle: 
Triglycerides, was estimated by “GPO-PAP TRINDER‟S METHOD”. The 
principle used in the estimation was, 
 
 Triglycerides                                Glycerol + Fatty acids 
 Glycerol +ATP                            Glycerol - 3 - Phosphate (G-3-P) 
 G-3-P +O2                                    H2O2 + Dihydroxyacetone Phosphate  
H2O2 + 4-Aminoantipyrine + ADPS               Blue Purple Complex + H2O  
 
Reagent and its components: 
The reagents provided in the kit included, Triglycerides reagent and 
Triglycerides standard (Conc.200 mg/dl). 
Sample used: Serum 
The components of the reagent were as follows; 
Lipase 5 KU/L 
Glycerol Kinase 1.25 KU/L 
Glycerol Phosphate Oxidase 5 KU/L 
Peroxidase 2  KU/L 
ATP 2 mmol/L 
4 –Aminoantipyrine 10 mmol/L 
ADPS (Phenolic Compound) 0.2 mmol/L 
GOODS Buffer (PH - 7) 20 mmol/L 
Surfactants  & Stabilizers  
 
GK 
POD 
        LPL 
GPO 
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Procedure: 
▪ The test tubes were arranged in a rack as per our need. The test tubes 
were labeled as Blank (B), Triglycerides standard (Conc.200 mg/dl), and 
Test samples (T1, T2 and so on as per the number of samples we had). 
▪ To the Blank (B) test tube 1 ml of Triglycerides reagent alone was 
added. To the Standard (S) test tube 10 µl of Triglycerides standard 
(Conc.200 mg/dl) was added following the addition of 1 ml of 
Triglycerides reagent. 
▪ To the Test (T) test tubes 1 ml of Triglycerides reagent was added and 
later 10 µl of the test serum samples were added in their respective tubes 
promptly in reference to the labeling. Then, the samples were incubated 
for 10 minutes at 37
o
C. 
▪ Following incubation the absorbance of the Standard (S), Test (T) was 
read against Blank (B) using the semi-autoanalyzer at 546 nm. 
BIORAD system parameters: 
Reaction mode End point 
Units mg/dl 
Wavelength  546 nm 
Blanking With  Reagent 
Flow Cell Temperature 37
o
C 
Sample Volume 10 µl 
Reagent Volume 1000 µl 
Linearity  1200 
Standard Concentration 200  
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The triglycerides value was calculated by the semi-autoanalyzer using the 
formula; 
                                                          ABSORBANCE OF TEST  
         TRIGLYCERIDES       =                                                                X 200 
                       (in mg/dl)                ABSORBANCE OF STANDARD 
 
Serum HDL Cholesterol estimation: 
Principle: 
HDL Cholesterol was estimated based on the “PHOSPHOTUNGSTATE 
PRECIPITATION METHOD”.  
 
Cholesterol ester + H2O                       Cholesterol + Free fatty acids 
Cholesterol ester + O2                          Cholest-4 ene 3-one + H2O2 
H2O2 + Phenol + 4-Aminoantipyrine  Red Quinoneimine Complex 
 
Reagent and its components: 
Cholesterol Oxidase 1 KU/L 
Cholesterol Esterase 0.6 KU/L 
Peroxidase 5 KU/L 
4 –Aminoantipyrine 0.5 mmol/L 
Phenol 20 mmol/L 
Phosphate Buffer (PH - 7) 50 mmol/L 
Phosphotungstic acid 0.6 mmol/L 
Magnesium chloride 25 mmol/L 
Triton X 100 0.1% 
Activators & Stabilizers  
  CEP 
CHOP 
 
POD 
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Sample used: Serum 
Procedure: Estimation of HDL Cholesterol involved 2 steps, 
Step 1: 
▪ The test tubes were arranged in a rack in order as per our need. The test 
tubes were labeled as per the number of serum samples we had. 
▪ Then, 0.2 ml of serum was taken and mixed thoroughly with 0.3 ml of 
precipitating reagent. The mixture was allowed to stand for 5 minutes. 
▪ Centrifugation was done at 3000 rpm for 10 minutes, so that we could 
get a clear supernatant. 
Step 2: 
▪ The test tubes as per our need were arranged in a stand. The test tubes 
were labeled as Blank (B), HDL Cholesterol Standard (Conc.50 mg/dl), 
and Test samples (T1, T2 and so on as per the number of samples we 
had). 
▪ To the Blank (B) test tube 1 ml of GenX Cholesterol reagent and 100 µl 
of distilled water was added. To the Standard (S) test tube 100 µl of 
HDL Cholesterol standard (Conc.50 mg/dl) was added following the 
addition of 1 ml of GenX Cholesterol reagent. 
▪ To the Test (T) test tubes 1 ml of GenX Cholesterol reagent was added 
and later 100 µl of the supernatants obtained from step 1 were added in 
their respective tubes promptly in reference to the labeling. 
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▪ Caution was taken by to ensure thorough mixing of reagent and the 
samples added. Then, the samples were incubated for 5 minutes at 37
o
C. 
▪ Following incubation the absorbance of the Standard (S), Test (T) was 
read against Blank (B) with semi-autoanalyzer (BIORAD) at 505 nm. 
The HDL cholesterol value was calculated by the semi-autoanalyzer using the 
formula; 
                                                                   ABSORBANCE OF TEST  
          HDL CHOLESTEROL =                                                                  X 50 
                       (in mg/dl)                      ABSORBANCE OF STANDARD 
 
BIORAD system parameters: 
Reaction mode End point 
Units mg/dl 
Wavelength  505 nm 
Blanking With  Reagent 
Flow Cell Temperature 37
o
C 
Sample Volume 100 µl 
Reagent Volume 1000 µl 
Linearity  150 
Standard Concentration 50  
 
Serum LDL Cholesterol estimation: 
LDL cholesterol was estimated using Friedewald‟s formula181; 
 
 
LDL = TC – HDL – [TG/5]2 
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ESTIMATION OF SOD: 
The principle behind the superoxide dismutase estimation done by us was 
inhibition of pyrogallol’s auto-oxidation by superoxide dismutase. 
Reagents used: 
▪ Tris buffer-50ml (containing 50 mM of tris&1 mM of EDTA). 
▪ Hydrochloric acid -50 ml to adjust the PH at 8.5.   
▪ Pyrogallol- 25 mg to 10 ml of distilled water (20 mM concentration). 
The millimolar (mM) solution was prepared by the formula; 
 
• Molecular weight of tris - 121.4 g/mol 
• Molecular weight of EDTA - 292.24 g/mol 
• Molecular weight of pyrogallol– 126.11 g/mol 
Procedure: 
For Control: 
 A total of 3 ml was made by the addition of 2.9 ml tris buffer with that 
of 0.1 ml pyrogallol solution and after ensuring thorough mixing of the 
two reagents, the readings were recorded at 420 nm exactly after 1 
minute 30 seconds and later at 3 minutes and 30 seconds.  
 The absorbance per 2 minutes was noted down and the pyrogallol‟s 
concentration was adjusted so as to achieve per minute change in 
absorbance to 0.020-0.023 nm. 
mM= Molecular weight (mg)/litre 
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For Sample: 
 Similarly, addition of 0.1 ml sample to 2.8 ml tris buffer, was done and 
following thorough mixing, 0.1 ml of pyrogallol solution was also added 
and mixed, then like the control reading, was taken at 420 nm, exactly 
after 1 minute 30 seconds and 3 minutes and 30 seconds.  
 The absorbance per 2 minutes was recorded. 
Then, the superoxide dismutase levels are analyzed from the 2 absorbance 
values (A,B)  measured at two minutes interval, 
                                                         ABSORBANCE (A-B) X 50 
                    SOD (in Units) =                   
                                                                 ABSORBANCE A 
 
ESTIMATION OF TBARS: 
Reagents used: 
▪ Trichloracetic acid -40% 
▪ Thiobarbituric acid- 0.67% 
Procedure: 
▪ The test tubes were arranged in a rack in order as per our need. 
The test tubes were labeled as per the number of serum samples 
we had. 
▪ Water bath was switched on and temperature was set at around 
90-100
o
C. 
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To 0.5 ml of serum sample, 0.5 ml of Trichloracetic acid and 2 ml 
of  Thiobarbituric acid were added very slowly. 
▪ The tubes were then kept in the boiling water bath for about 10 
minutes. After 10 minutes, the tubes were brought back to the 
room temperature. 
▪ Centrifuged of the samples were done for 10 minutes at 3000 
rpm. From the centrifuged samples the supernatant was separated. 
The readings were taken using colorimeter at 540 nm. 
                                                                     ABSORBANCE AT 532nm X 105 
             MALONDEHYDE (in Units) =                    
                                                                                               1.56 
 
RAT NUCLEAR FACTOR-KAPPA B (NF-κB) ELISA KIT: 
Principle of the assay: 
 This assay was a quantitative sandwich enzyme immunoassay technique 
done by ELISA kit [Cusabio,China]. The microplate provided was pre-coated 
with NF-κB specific antibody. NF-κB present on the standards and samples 
when pipetted into the wells would bind to antibody that was immobile. After 
removal of the substance that were not bound, a biotin-conjugated antibody 
specific for NF-κB would be pipetted into the wells. Subsequently, wells were 
washed and addition of Horseradish Peroxidase (HRP) done. An addition of 
substrate solution to the wells would lead on to color development that would 
be in proportion to bound NF-κB, and the color intensity was measured. 
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Detection range: 1.56 pg/ml-100 pg/ml. 
Materials provided: Caution was taken to keep the kit at 2-8
o
C. 
Reagents Quantity 
Assay plate (12x8 coated wells) 96 wells 
Standard (Freeze dried) 2 
Biotin-antibody(100x concetrate) 120 μl 
HRP-avidin (100 x concentrate) 120 μl 
Biotin-antibody Diluent 15 ml 
HRP-avidin Diluent 15 ml 
Sample Diluent 50 ml 
Wash Buffer (25 x concentrate) 20 ml 
TMB Substrate 10 ml 
Stop Solution 10 ml 
 
Sample Used: Serum  
Sample preparation:  
 Serum samples stored at -20
o
C were freeze thawed before starting and 
required a dilution of about 20-fold into the provided sample diluent, this was 
achieved by the addition of 15μl sample to 285μl diluent. 
Reagent preparation: 
 All reagents were brought to the room temperature (18-25°C) before use 
and fresh standard was prepared before the assay. Standards were reconstituted 
according to the instruction in the manual, so as to avoid foaming. The 
preparation for reagents or samples was made using distilled water. 
 Biotin-antibody-Centrifuged done prior to opening of the vial. For the 
assay Biotin-antibody required a 100-fold dilution and the suggested 
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100-fold dilution was obtained by addition of 10 μl of Biotin-antibody 
with 990 μl of Biotin-antibody diluent.  
 HRP-avidin-Centrifuged was required. HRP-avidin also required a 
dilution of about 100-fold, done by adding 10 μl HRP-avidin to 990 μl 
of  its diluent.  
 Wash Buffer-Brought to room temperature and mixed gently until the 
crystals were completely dissolved. 20 ml of Wash Buffer Concentrate 
was diluted with distilled water to prepare 500 ml of Wash Buffer.  
Standard Preparation: 
▪ Centrifugation of the vial at 6000-10000rpm for 30s. Standard was 
then reconstituted with 1.0 ml sample diluent to get a stock solution 
of  100 pg/ml.  
▪ After complete reconstitution the standard was mixed thoroughly and 
allowed to settle for 15 minutes.250 μl of sample diluent was 
pipetted into 7 test tubes. 
▪ The standard that had not been diluted served as the highest standard  
(100 pg/ml) and on the other hand sample diluent as zero standard (0 
pg/ml). 
Assay procedure: 
▪ First prepared all the reagents, working standards, and samples as 
directed in the previous sections. Added 100μl of standard and 
sample into each well. 
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▪ Then they were kept aside for 2 hours incubation at 37°C. After 2 
hours they were removed, but not been washed. 
▪ Added Biotin-antibody of about 100μl into each of the wells, and 
incubated for about 1 hour at room temperature (37°C).  
▪ Later each well was washed thrice, with wash buffer (200μl) using a 
multi-channel pipette, and allowed to stand for about 2 minutes. At 
the end, remaining wash buffer was removed by blotting it against 
clean tissue papers.  
▪ Subsequently, added 100μl of HRP-avidin and was incubated for 1 
hour at 37°C. Repeated the wash process for about five times as that 
performed earlier. 
▪ Added TMB Substrate 90μl and incubated at room temperature 37°C 
for about 15-30 minutes, in addition, taken care to protect from light. 
The change of color produced after adding TMB Substrate from light 
blue to gradations of blue was noted.  
▪ Subsequently addition of 50μl stop solution to each well and gently 
the plate was taped to ensure thorough mixing had produced a 
transition of colour from blue to yellow. 
▪ Optical density was determined within 5 minutes, using a microplate 
ELISA reader set to the wavelength 450 nm with wavelength 
correction at 540 nm or 570 nm. 
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Histopathology of liver and heart: 
The animals to be sacrificed for histopathological examination were 
anaesthetized with ether before the procedure. Once the level of anaesthesia is 
certain, the rats were dissected and the organs liver and heart were collected 
separately in a promptly labeled sterile container with formalin. Those 
specimens were immediately sent for histopathological examination. 
 Paraffin blocks were made and 4 thick sections were made from the 
chosen blocks for routine haematoxylin and eosin staining. Reagents required 
for this staining were Harris haematoxylin and eosin. 
Procedure: 
 Deparafinisation and subsequently hydration were done with xylene and 
alcohol along with water respectively. 
 Slides were stained with Harris haematoxylin stain for 10 minutes. After 10 
minutes they were washed in tap water (for 5 minutes) until the sections 
become blue. 
 Differentiation was done with 1% acid alcohol (mixture of 1% hydrochloric 
acid in 70% alcohol) for 10 seconds, later washed in tap water (for 10 
minutes). 
 Bluing the slides was done by immersing in ammonia water followed by 
washing them in tap water for 5 minutes. 
 Eosin staining for 10-15 minutes followed by washing in running tap water 
for 3 minutes. Subsequently dehydration through graded alcohols, clearing 
and mounting was done. 
  
 
 
 
 
 
 
 
 
 
 
Results 
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RESULTS: 
STATISTICAL ANALYSIS: Done using IBM-SPSS software version 22. 
The analysis done was Paired-t-test for analyzing the paired data i.e., 
parameters before and after induction and also for comparing data at the end of 
treatment with that following induction. 
One-way ANOVA and post hoc LSD were done to analyze the difference 
between groups. 
 
GROUPING OF ANIMALS 
 
 
GROUP I 
MOMORDICA 
CHARANTIA 
300 mg/kg/day 
[N=10]
GROUP II 
MOMORDICA 
CHARANTIA 
600 mg/kg/day 
[N=10]
GROUP III 
STANDARD 
TREATMENT 
[N=8]
GROUP IV 
NORMAL 
CONTROL  
[N=6]
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BODY WEIGHT: 
There was an increase in mean body weight from 181.36 to 318.25g 
after a period of 6 weeks in animals [N=28] on 66% fructose diet. The mean 
increase in body weight was around 136.15±22.75g [N=28] in animals induced 
with fructose diet against 66.83±14.36g in normal control [N=6] [Figure-1]. 
 
Figure-1: Body weight change during induction of metabolic syndrome 
 
 
 
 
 
183
192
204
217.83
233.67
239.5
249.83
181.36
189.89
205.39
228.39
259.71
295.07
318.25
170
180
190
200
210
220
230
240
250
260
270
280
290
300
310
320
330
WEEK 0 WEEK 1 WEEK 2 WEEK 3 WEEK 4 WEEK 5 WEEK 6
B
O
D
Y
 W
E
IG
H
T
 [
in
 g
ra
m
s]
BODY WEIGHT [in grams]
NORMAL CONTROL [N=6] INDUCTION GROUP [N=28]
 57 
 
Body weight change in individual groups on induction: 
 An increase in body weight was established during the 6 weeks induction 
period in all the 3 groups of animals fed on 66% fructose diet in comparison to 
normal control animals with the maximum weight gain in Group II rats 
[330.1±16.5 grams] [Figure-2]. A paired-t-test showed a statistically significant 
[P <0.001] increase in body weight in all the 3 groups [Annexure-Table-1]. 
 
Figure-2: Body weight change during induction of metabolic syndrome 
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Body weight in individual groups after treatment: 
A decrease in body weight was noted in all the 3 groups treated with 
low dose, high dose M.charantia and standard therapy in comparison to normal 
control animals [Figure-3]. 
 
Figure-3: Body weight change following induction and treatment 
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Animals on low dose and standard therapy demonstrated a reduction in 
body weight to the level of normal control while high dose M.charantia despite 
a statistically significant reduction [P=0.011] did not attain a mean that was not 
statistically significant from that of normal control [Table-1]. In contrast, 
normal control rats showed a linear weight gain. 
 ANOVA (Analysis of variance) was done to assess the significant change 
in body weight between groups at three sessions i.e., baseline, following 
induction and following treatment.  
 At baseline there was no statistically significant difference in weight 
between groups. Following induction with 66% fructose all the three groups 
showed a statistically significant increase in body weight compared to normal 
control [P=0.001, 0.033, 0.000 respectively].  
 Further, following treatment though all the three groups showed 
reduction, body weight of Group I rats on M.charantia 300mg/kg/day and 
Group III rats on Standard treatment reached the level of normal[Table-5]. 
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BODY MASS INDEX [BMI]: 
An increase in BMI was evidenced after a period of 6 weeks in animals 
[N=28] on 66% fructose diet in comparison to the normal control animals with 
a mean difference of 0.132 g/cm
2
. The increase in BMI was from 0.407 to 0.66 
in animals fed on fructose diet while the rise in BMI seen in normal rats was 
from 0.425 to 0.528 g/cm
2
only which can be accounted to the weight gain 
during the normal growth phase of rats in this group [Figure-4].  
 
Figure-4: Change in BMI during induction of metabolic syndrome 
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BMI change in individual groups on induction: 
An increase in body mass index was established during the 6 weeks 
induction period in all the 3 groups of animals fed on  fructose diet in 
comparison to normal control animals with the maximum change in BMI 
observed in Group II rats [0.683±0.048grams] [Figure-5]. 
  
Figure-5: Change in BMI during induction of metabolic syndrome 
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Figure-6: BMI in individual groups after treatment 
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 Following treatment for a period of 6 weeks [Figure-6], when compared 
with induced animals, Group I rats on M.charantia 300 mg/kg/day, Group II 
rats on M.charantia 600 mg/kg/day and Group III rats on Standard treatment 
showed a statistically significant reduction [P =0.021,P =0.001 and P=0.020 
respectively] in BMI [Table-1].In contrast to all the treatment groups, the 
untreated normal control animals showed a statistically significant increase in 
BMI [P <0.001][Table-1]. 
 ANOVA (Analysis of variance) was done to assess the significant change 
in BMI between groups. At baseline there was no statistical significant 
difference in BMI between groups. Following induction with 66% fructose all 
the three groups showed a statistically significant increase in body mass index 
compared to normal control [P <0.001].  
 Further, following treatment, though all the three groups showed 
reduction in body mass index, there was no statistically significant difference 
when compared to control [P=0.441,0.064,0.651 respectively] indicating 
normalization of BMI [Table-6]. 
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FASTING BLOOD SUGAR: 
Change in fasting blood sugar in individual groups on induction: 
 All the 3 groups showed a statistically significant increase in fasting 
blood sugar [P <0.001] from the baseline on induction of the disease [Table-1] 
been illustrated in the chart [Figure-7]. 
Figure-7: Change in fasting blood sugar during induction 
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Change in fasting blood sugar in individual groups on treatment: 
 There was a marked reduction in fasting blood sugar observed among all 
the groups of animals treated. The chart delineates the extent of fasting blood 
sugar in groups II and III towards normalization [Figure-8].  
  
Figure-8: Change in fasting blood sugar during treatment 
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 While following treatment of the animals for a period of 6 weeks all the 
three groups [Groups I,II and III] a paired t test detected a statistically 
significant reduction in fasting blood sugar [P <0.001] [Table-1], while the 
normal control group did not show significant change in blood sugar [P 
=0.610]. 
 The difference in fasting blood sugar between groups was analyzed using 
ANOVA showed that a statistically significant increase [P <0.001] in all the 3 
groups when compared to normal control on induction. Following treatment, 
Group II and III had reduced fasting blood sugar to a level similar to normal 
control [P=0.250,0.457 respectively], while reduction of the fasting blood sugar 
by M.charantia low dose (Group I) was not to the extent of that of normal 
control[Table-7]. 
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MEAN ARTERIAL PRESSURE [MAP]: 
 
Change in MAP in individual groups on treatment following induction: 
Though all the 3 groups of animals fed on 66% fructose diet showed an 
increase in Mean arterial pressure (MAP) from the baseline within6 weeks, the 
induction was not homogeneous among all the groups with maximum rise in 
standard treatment group [Figure-9]. A paired-t-test showed a statistically 
significant increase [P=0.006] only in the animals assigned to standard 
treatment group in comparison to baseline values [Table-2]. 
 
Figure-9: Change in MAP during induction and treatment 
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 A paired-t-test was done to compare the difference in MAP following 
treatment found that the reduction though evident, was statistically significant 
in none of the groups [P =0.707, 0.173, 0.065] from the period of induction 
[Table-2]. 
 
Figure -10: Change in MAP during induction and treatment 
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SERUM TRIGLYCERIDES: 
Serum triglycerides on induction and treatment of metabolic syndrome: 
All the 3 groups showed a statistically significant increase in 
triglycerides [P <0.001] from the baseline following induction of metabolic 
syndrome with 66% fructose diet for a period of 6 weeks [Figure-11]. 
 
Figure-11: Change in triglycerides levels on induction and treatment 
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Figure-12: Change in triglycerides levels on induction and treatment 
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TOTAL CHOLESTEROL LEVELS: 
 Similar to triglycerides, total cholesterol of all the 3 groups showed a 
statistically significant increase [P <0.001] from the baseline following 
induction [Figure-13]. Compared to the normal control, Groups II and III on 
treatment showed a statistically significant [P=0.001] reduction [Table-2] in 
total cholesterol, while the reduction in Group I rats on M.charantia 300 
mg/kg/day (low dose) failed to demonstrate statistical significance [P=0.085]. 
 
Figure-13: Change in total cholesterol following induction and treatment 
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Figure-14: Total cholesterol levels following induction and treatment 
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LDL CHOLESTEROL LEVELS: 
Following induction and treatment of metabolic syndrome: 
 All the 3 groups showed a statistically significant increase in LDL [P 
<0.001] from the baseline following induction of metabolic syndrome with 
66% fructose diet for a period of 6 weeks [Figure-15].  
 
Figure-15: Change in LDL levels following induction and treatment 
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Figure-16: Change in LDL levels following treatment 
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 Further, following treatment, Group II and III, when compared to control 
showed a statistically significant reduction in LDL [P=0.476,0.130 
respectively] indicative of normalization of LDL levels while Group I animals 
on M.charantia low dose did not show significant reduction in LDL to the level 
of normal control[Table-11]. 
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HDL CHOLESTEROL LEVELS: 
Following induction and treatment of metabolic syndrome: 
 Comparison of serum HDL levels done among all the 3 groups showed a 
statistically significant reduction [P <0.001] at the time of disease induction to 
baseline levels [Figure-17].  
 
Figure-17: Changes in HDL levels following induction and treatment 
 
  
 A paired-t-test showed a statistically significant increase in mean HDL 
levels [P =0.001, 0.001, and 0.003 respectively] at the end of treatment when 
compared to the mean following the period of induction, while normal control 
did not show statistically significant change in HDL levels [P=0.161][Table-3].  
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Figure-18: HDL levels on induction and treatment of metabolic syndrome 
 
 
 
 
 ANOVA done to evaluate the significant change in HDL levels between 
groups showed a significant reduction in HDL levels [P <0.001] compared to 
normal control following induction and after treatment, there was an increase 
in HDL levels all the 3 treatment groups [Figure-18], despite this increase the 
mean HDL cholesterol in Groups II was not statistically significant compared 
to normal control rats indicating normalization of HDL level in this group at 
the end of treatment [P=0.808] [Table-12]. 
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THIO-BARBITURIC ACID REACTIVE SUBSTANCE LEVELS: 
 A paired-t-test had shown a statistically significant increase in Thio-
barbituric acid reactive substance, Malondialdehyde (MDA) in all the 3 groups 
[P=0.007,0.001,0.003] [Table-3] from the baseline following induction of 
metabolic syndrome with 66% fructose diet over a 6 weeks period [Figure-19]. 
 
Figure-19: TBARS during induction and treatment of metabolic syndrome 
 
 Following treatment period of 6 weeks, a paired t test was done to detect 
the difference between groups found that though all the three groups had 
reduced the TBARS levels, it was only II and III showed a statistically 
significant reduction of malondialdehyde levels [P=0.024, 0.001] respectively.
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 While the group I animals on low dose M.charantia did not show 
significant reduction [P=0.066] in malondialdehyde in comparison to the other 
groups [Table-3]. 
 
Figure-20: Change in TBARS during treatment of metabolic syndrome 
 
 ANOVA done to assess the significant change in MDA levels between 
groups revealed a statistically significant rise in the levels of MDA [P =0.002, 
<0.001,<0.001 respectively] compared to normal control following induction 
[Figure-20]. Following treatment, the MDA levels in all the 3 treatment groups, 
was not statistically significant different from that of normal controls indicating 
normalization of MDA level all the groups at the end of 
treatment[P=0.078,0.743,0.454 respectively] [Table-13]. 
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SUPEROXIDE DISMUTASE [SOD]: 
SOD following induction and treatment of metabolic syndrome: 
 All the 3 groups showed a statistically significant reduction in SOD 
levels [P=0.001, 0.005, 0.000 respectively] [Table-4] from the baseline 
following induction of metabolic syndrome with 66% fructose diet [Figure-21] 
for a period of 6 weeks when tested using paired-t-test. 
 
Figure-21: Changes in SOD levels on induction and treatment 
 
 
 Following treatment period for 6 weeks, all the 3 groups though showed a 
increase in SOD levels from the period of induction, but was not of statistical 
significance when a paired t test was used to test the significance 
[P=0.087,0.107,0.214 respectively] [Table-4]. 
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Figure-22: Changes in SOD levels on induction and treatment
 
 
 When ANOVA was done to evaluate the significant change in SOD levels 
between groups following induction, a statistically significant reduction in 
SOD levels [P=0.020, 0.001, 0.000 respectively] was detected compared to that 
of normal control. After treatment, there was an increase in SOD levels in all 
the 3 treatment groups [Figure-22], with the increase in the mean SOD 
cholesterol in Groups I and II not being statistically significant compared to 
normal control rats indicating normalization of SOD level in this group at the 
end of treatment [Table-14]. 
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NUCLEAR FACTOR KAPPA-B [NF-κB]: 
 
NF-κB following induction and treatment of metabolic syndrome: 
 The mean serum NF-κB levels of the normal control animals in 
our study at baseline was established as 22.033±5.657 pg/ml [Figure-23].All 
the 3 groups showed a increase in NF-κB levels, but not of statistical 
significance [P=0.303, 0.270 and 0.327 respectively] from the baseline 
following induction when a paired-t-test was used [Table-4].In comparison to 
the normal control values in their individual groups, all the 3 groups showed a 
statistically significant reduction in serum NF-κB levels [P=0.043, 0.001 and 
0.027 respectively] [Table-4]. 
 
Figure-23: Normal serum NF-κB levels [in pg/ml] observed in our study 
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 ANOVA done to analyze the difference between groups had found that 
there was a reduced serum NF-κB levels, which is not statistically significant 
when compared to normal control rats indicating normalization of serum NF-
κB levels in groups I and III at the end of treatment, while group III animals 
showed a statistically significant difference with that of normal control 
indicating non-achievement on normalization [Table-15]. 
 
HISTOPATHOLOGICAL EXAMINATION: 
Histopathological changes in liver: 
 On comparing the liver of treated animals with that of normal control, 
all the 3 groups showed fatty infiltration [micro & macrovesicular steatosis]. 
Group II and III animals showed fatty changes of grade 2+ while the fatty liver 
was graded as 3+ in Group I animals treated with low dose M.charantia 
[Figure-25-Annexure]. 
Histopathological changes in heart:  
 On comparing the histopathology of heart of the treatment groups with 
that of normal control, it was evident that all the 3 groups showed hypertrophy 
of heart due to fructose diet. The grade of hypertrophy was found to be 
homogenous in Groups I, II and III and did not any show any changes related 
to reversal of the hypertrophied heart. But the fatty change that is observed in 
the disease control is not seen in sections of Groups I, II and III heart[Figure-
26-Annexure]. 
 
  
 
 
 
 
 
 
 
 
 
 
Discussion 
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DISCUSSION: 
 The aim of our work was to study the biological basis of effects of 
Momordica charantia in metabolic syndrome by measuring serum NF-κB, 
lipid derived aldehydes and superoxide dismutase levels. And we also focused 
to identify the therapeutic advantage, of M.charantia as a sole agent in the 
treatment of all the entities of metabolic syndrome with respect to available 
standard treatment, by ascertaining the changes in body mass index, fasting 
blood sugar, lipid profile and blood pressure. 
 A total of thirty four male Sprague-Dawley rats, weighing 150-200 mg 
were included in our study and were randomly assigned into 4 groups, with 10 
animals each in M.charantia low and high dose [300 mg/kg/day & 600 
mg/kg/day] groups, 8 animals in standard treatment group with 6 animals in 
normal control group. For a period of first 6 weeks, all the animals except the 
normal control were fed on 66% fructose diet. Further, these animals were 
treated based on the group they belonged to, for a period of 6 weeks. 
 There was statistically significant rise in body weight following induction 
of metabolic syndrome in animals on 66% fructose diet for 6 weeks [P<0.001] 
[Table-1]. In our study a significant increase in body weight from181.65 
±18.51 g to 317.80 ±16.94 g [Figure-1] in fructose fed rats was detected. 
Previous studies had also observed that following treatment with 66% fructose 
diet, an increase in mean body weight from 162.7±8.8 g to 272.4±9.2 g
182
. The 
reason for the weight gain was established as leptin resistance, as evidenced by 
high serum levels in studies. Leptin, the hormone responsible for reduced food 
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intake and reduction in body weight, being inhibited by triglycerides that 
increased on fructose intake explains the syndicate between fructose intake and 
obesity
183
. 
  A reduction in body weight was observed in all the treated groups in 
comparison to induction with statistical significance only in Group-II animals 
on high dose M.charantia 600 mg/kg/day[Table-1]. In comparison between the 
treated animals and normal age controls, the reduction was to the level of 
normal control in low dose M.charantia and standard treatment group, but it 
was not so with animals on M.charantia 600 mg/kg/day (high dose). This 
reason was due to the fact that, this group of animals had shown a maximum 
weight gain following induction and though the mean reduction in weight was 
apparently similar to other groups, it was not to the extent of normalization 
[Table-5]. The probable mechanism of weight reduction produced by 
M.charantia was found in a study to be significant reduction in plasma insulin 
and leptin levels along with increased IRS, PI3K and GLUT4 protein 
expression in myocytes thus averting insulin resistance and leptin resistance
184
. 
 Body mass index was determined using body weight and nose-to-anus 
length showed a statistically significant [P <0.001] increase in all the groups of 
animals after an induction period of 6 weeks with 66% fructose diet and also in 
the control animals compared to baseline values[Table-1]. The increase in BMI 
was similar to the effect observed in previous studies. The increase in BMI 
noted in normal control can be explained as due to the linear growth that is 
normally observed
110
.  
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 Following treatment of metabolic syndrome for a period of 6 weeks, all 
the treated groups of animals i.e., group I rats on M.charantia 300 mg/kg/day, 
group II rats on M.charantia 600 mg/kg/day and group III rats on Standard 
treatment showed a statistically significant reduction [P =0.021,P =0.001 and 
P=0.020 respectively] [Table-1] in BMI. Inspite of not achieving statistical 
significance in body weight reduction in the Groups I and III, BMI showed a 
significant reduction and this disparity can be accounted by the fact that the 
length and the thoracic circumference would become static at around 4-5 
months and thus, signifying the advantage of BMI over body weight, as diet 
induced obesity could be easily estimated from the BMI in rats in addition to 
being a predictor of dyslipidemia and oxidative stress
185
. 
 In our study, fasting blood sugar was estimated every week for a period 
of 12 weeks and statistically significant changes, if any observed, was 
determined at baseline, induction and following treatment. All the 3 groups that 
were provided with high fructose diet showed a statistically significant increase 
in fasting blood sugar [P <0.001] from the baseline to induction. It is well 
established that the enzyme fructokinase, would phosphorylate the surplus 
fructose absorbed from the intestine. And also, the metabolism pertaining to 
fructose is not similar to that of glucose, the difference being fructose-1-
phosphate that is formed from fructose would be converted to several 3-carbon 
molecules, like glyceraldehyde, glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate and they are considered as the potential source for 
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gluconeogenesis, and thereby raise blood glucose levels
186
. 
 Following treatment of the disease for a period of 6 weeks, all the three 
groups [Groups I,II and III] showed a statistically significant reduction in 
fasting blood sugar [P<0.001], while the normal control group did not show 
significant changes [P=0.610] in comparison to the time of induction[Table-1]. 
A study which was done earlier to analyze the anti-diabetic effect of 
M.charantia with reference to glibenclamide found that all the doses used in 
the study from lower to higher doses [250 mg/kg, 500 mg/kg, 750 mg/kg] 
showed a statistical significant reduction in blood sugar similar to that resulted 
from our study
187
. 
  On comparison of the mean of treated groups to normal age control at the 
end of treatment, it was evident that, though M.charantia low dose had reduced 
the blood sugar significantly but not to the extent of normalization [Table-7]. 
The probable reason for this could be due to shorter duration of treatment. 
There are numerous studies demonstrating hypoglycemic activity of 
M.charantia, apart from the observation that the active component being 
structurally similar to insulin. Accordingly, it is also shown to exhibit insulin 
secretagogue action with additional activity of inhibiting two key 
gluconeogenic enzymes fructose 1, 6-diphosphatase and glucose-6-
phosphatase
84,188
. 
 Our study animals though have demonstrated an increase in Mean 
arterial pressure in response to high fructose diet, the rise was not identical in 
all the groups of animals and there was inter and intra group variation with 
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statistically significant [P=0.006] rise in animals grouped for standard therapy 
(Group III). Though studies had demonstrated the induction of hypertension by 
fructose diet, contradictorily, there are also studies demonstrating inconsistent 
elevation of blood pressure
189,190
.A study done in male Sprague-Dawley rats 
with high fructose diet showed a demonstrable rise in systolic blood pressure 
but not mean arterial pressure (MAP) which was rationalized by the variability 
between animals and also the scale of metabolic dysfunction not being 
sufficient to defer an effect on blood pressure
189
.The probable reason for the 
increased MAP response in Group III rats unlike the other groups in our study, 
would have been due to the associated rise in serum triglycerides. Similar 
observation was also made in a previous study
191
. 
 Subsequently after the treatment period of 6 weeks, all the 3 groups of 
animals [groups I, II and III] showed a reduction in mean arterial pressure [P = 
0.707, 0.173 and 0.065] from the period of induction though not statistically 
significant [Table-2]. 
 When the difference between groups were analyzed at the end of 
treatment, a constructive finding illustrated in our study was that group II and 
III animals on high dose M.charantia and standard therapy showed a reduction 
in MAP to the level of normalization, while low dose M.charantia in contrast 
showed a rise in blood pressure following a fall indicative of its inconsistency 
in treating hypertension [Table-8]. 
 There exists an analogous pattern of MAP changes in the groups II and III 
in the line chart indicating a potentially similar mechanism of BP lowering by 
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M.charantia and telmisartan. This could be explained by a recent study 
signifying the existence of a peptide named VY-7 in M.charantia that 
possesses antihypertensive property by inhibiting angiotensin converting 
enzyme
104
, and in turn reducing aldosterone production. In addition, naturally, 
it has high potassium content and both could be contributory to increased 
natriuresis and thereby a fall in blood pressure. Telmisartan, an angiotensin 
receptor antagonist, also acts similarly by reducing aldosterone production. 
Yet, another homology that exists between telmisartan and M.charantia is that 
both possess PPAR γ agonistic activity.  
 Our study evinced a statistically significant increase in triglyceride levels 
[P <0.001] from 60.95±9.27 mg/dl at baseline to 222.97±64.34 mg/dl at 
induction of metabolic syndrome [Table-2] as consistent with another study 
wherein serum triglycerides increased from 80.07 ±1.68 mg/dl to 191.46 ±1.66 
mg/dl with high fructose diet
192
. It had been documented earlier with studies 
that mechanism of fructose induced gluconeogenesis and hypertriglyceridemia 
were interlinked. The analogy that exists is that 3 carbon molecules formed 
from fructose-1-phosphate could be utilized eventually in the formation of fatty 
acids and glycerol, which on esterification would form triglycerides. There 
could be few other mechanistic contributions, for instance, either up regulation 
of lipogenic pathway or down regulation of PPAR-α activity involved in 
catabolism of triglycerides
192
. 
 Subsequently after the treatment period of 6 weeks, all the 3 groups of 
animals [Groups I, II and III] showed a statistically significant reduction in 
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triglycerides [P <0.001] from the period of induction. When all the three 
treated groups were compared to normal age control after treatment, it was 
evident that, M.charantia low, high doses and standard treatment had reduced 
the triglycerides to the extent of normalization [Table-9]. Yet, another study 
evaluating the hypolipidemic effects of M.charantia showed a similar 
reduction including low dose of 300 mg/kg as with our study
193
. The milieu of 
reduction in triglyceride levels caused by bitter melon was due to increased 
expression of PPAR-α activity in the liver. As a sequel of increased activity of 
PPAR-α, the key receptor in down regulation of apolipoprotein C-III involved 
in hydrolysis of triglycerides by lipoprotein lipase (LPL) contributed to the 
lipid-lowering effect of M.charantia
101,194
. 
 All the 3 groups of animals included in our study had attained a 
statistically significant increase in total cholesterol levels [P <0.001] from the 
baseline value of 98.21±8.26 mg/dl to 209.63±28.67 mg/dl following induction 
of metabolic syndrome [Table-2] which was same as that observed in previous 
studies with high fructose diet induction
191,195
. The reason behind the elevation 
of total serum cholesterol level by fructose as a retort to the increased weight 
and insulin resistance which would lead on to activation of the enzymes HMG 
CoA reductase and fatty acid synthase along with increased expression of 
hepatic sterol response element binding protein (SREBP)
196
. 
 Compared to the normal control, group II and group III animals on 
showed a statistically significant [P=0.001] [Table-2] reduction in total 
cholesterol, while Group I rats on M.charantia low dose had not shown any 
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statistical significant reduction [P=0.085] and further the results of a study 
done on off springs of rats fed with 66% fructose diet showed that bitter melon 
had significantly reduced the total cholesterol as seen with our study
197
.On 
comparing the groups with that of normal animals at the end of treatment 
period revealed the reversal of serum cholesterol level to the degree of 
normality in those animals on high dose M.charantia and standard treatment 
[Table-10]. The probable mechanism as demonstrated by an earlier study is 
inhibition of the bile acid reabsorption, thereby leading on to increased 
elimination of bile acids in feces. In addition, it is also known to regulate 
cholesterol 7α-hydroxylase (CYP7A1) by increasing the level of hepatic 
CYP7A1 mRNA expression contributing to increased conversion of 
cholesterol to bile acids
198
. 
 This study also elucidated a statistically significant increase in LDL 
levels in all the 3 groups [P <0.001] from the baseline following fructose diet 
[Table-3], a similar effect was produced earlier in another study. The 
perception behind the occurrence of increased LDL with fructose is that at 
large amounts it would undergo glycation rather than fructation, which is 
considered to be detrimental to the cellular proteins by the production advanced 
glycation end products (AGEs)
199
, thereby furnishing oxidative damage. Once 
the LDL is glycated, they are poorly recognized by the lipoproteins and 
scavenging receptors, which consequentially leads on to increased LDL 
levels
200
. 
 After a treatment period of 6 weeks, Group II and Group III animals 
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showed a statistically significant reduction in LDL [P <0.001] from the period 
of induction while Group I animals on M.charantia low dose did not show 
significant reduction [P=0.366] [Table-3]. It was also found that compared to 
normal control animals, normalization of LDL levels in M.charantia high dose 
and the animals on standard treatment was seen but not with low dose bitter 
melon [Table-11]. This action of M.charantia could be justified by its 
antiglycating activity proven by a study that demonstrated the percentage 
inhibition of AGE as 40% at 1 mg/ml concentration by AGE fluorescence
201
. 
Furthermore, Momordin (charantin), the active component of bitter melon, by 
promoting PPARδ activity decreases LDL, with subsidiary action of decreased 
primary lipoprotein of LDL apolipoprotein B (Apo B) production, and 
apolipoprotein C- III expression on VLDL
202
. 
 Comparison of serum HDL levels among all the groups of our study at 
the level of induction, showed a statistically significant reduction in HDL 
levels [P <0.001] with reference to the baseline values [Table-3] and this result 
was homogenous to that of former studies
203
. It has been well entrenched by 
studies that caveolins are found to be involved in the export of bile salts from 
the liver, and there exists a concordant relationship between exportation of bile 
salts and HDL levels i.e., any reduction or increment in the earlier would lead 
on to reduction or increase of the HDL levels respectively. Based on this 
mechanism, ingestion of high fructose diet would lower the HDL levels by 
reducing the bile salt export
204
. 
 Following treatment for 6 weeks, all the 3 groups showed a statistically 
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significant increase in HDL levels [P =0.001, 0.001 and 0.003 respectively] 
from the period of induction [Table-3] as observed in earlier study
205
. On 
comparison of normal control animals with that of the other groups at the end 
of treatment revealed that the restoration of serum HDL level to the degree of 
normality in those animals on high dose M.charantia but not with low dose and 
standard treatment [Table-12]. In adipocytes, the enzyme lipoprotein lipase was 
responsible for both release of fatty acid and conversion of VLDL to 
cholesterol-rich LDL. Normally, macrophages embedded in the vessel wall 
would take up VLDL and ox-LDL actively and excess cholesterol would then 
be fluxed out through the HDL pathway. As demonstrated by studies that the 
balance between lipid influx and efflux is carried out by PPAR-γ in humans 
and PPAR-δ in lower animals. Any agent with the PPAR agonistic activity 
would increase HDL levels by decreasing LDL and M.charantia is one such 
agent with PPAR-δ agonistic activity thus reducing HDL levels202. 
 The estimated levels of thiobarbituric acid reactive substance 
malondialdehyde (MDA) when compared at induction with that of baseline 
showed a statistically significant rise [P=0.007,0.001 and 0.003respectively] 
[Table-3]. It was well recognized by studies that the animals fed on high 
fructose diet were known to produce remarkable changes in serum triglyceride 
levels, which in turn would increase the activity of fatty-acyl-coA oxidase 
leading on to β-oxidation. Further, excess usage of non-esterified fatty acid 
(NEFA) for β-oxidation would lead on to the down-regulation of malonyl-CoA, 
and the reduced NEFA transport via CPT-1 across mitochondria thereby 
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increasing oxidation at endoplasmic reticulum and peroxisomes. In addition, 
oxidation of organelles in the cytoplasm releases ROS, which when formed in 
excess, damages the mitochondrial membrane rich in polyunsaturated fat thus 
serving as a source for lipid peroxidation derived aldehydes. However, the 
process does not terminate there, as those systemically released MDA would 
inhibit the defensive anti-oxidant enzymes SOD and catalase
206
. 
 Following treatment for a period of 6 weeks Groups II and III showed a 
statistically significant decrease in lipid derived aldehydes [P=0.024, 0.001 
respectively]. Analysis done to scale the difference between groups revealed no 
statistically significant difference between the treated groups and normal 
control indicating the normalization of lipid peroxidation [Table-13]. Ours is 
the first study to demonstrate the effect of M.charantia on Lipid derived 
aldehydes in metabolic syndrome model even though the mechanism 
contributing to the effect has been studied. 
 Superoxide dismutase estimation done in our study revealed a 
statistically significant decline in their levels during the span of induction with 
fructose [P=0.001, 0.005 and 0.000 in 3 groups respectively] [Table-4]. It was 
recognized that ROS plays a key role in regulating various cellular functions 
but at higher concentration are responsible for disruption of structural integrity 
of cells and thereby damage the proteins, DNA and lipid. Any condition that 
disrupts this balance could lead on to oxidative stress by causing profound 
reduction in the enzyme superoxide dismutase, one such state is hyperglycemia 
induced by high fructose diet
207
.  
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 The subsequent determination of enzyme levels following the treatment 
period though endowed ascend in their serum levels did not achieve statistical 
significance when compared to the values at induction [Table-4]. When we 
analyzed the difference in mean superoxide dismutase levels between the 
treated and age control rats, there was no statistically significant difference 
indicative of its acceleration towards normal with both the doses of 
M.charantia. While the standard therapy did not favorably usher the free 
radical scavenger, superoxide dismutase towards the expected magnitude 
[Table-14], the reason could be credibly due to the mean reduction in their 
level was huge at the time of induction with respect to other two groups. 
 In our study, serum NF-KB levels were estimated using ELISA kit at the 
baseline (0 week), on induction (6 week) and following treatment (12 week). 
Though there are studies on tissue expression of NF-κB, subsequent to 
infections, inflammation and malignancies, there is only sparse literature 
available on serum levels of NF-κB till date. A study done in rats with 
mucositis on inflammatory markers including serum NF-κB found that there is 
difference between groups at baseline as in concordance with our study
208
.The 
mean serum level at baseline was established as 22.033±5.657 pg/ml [Figure-
23] in our study. All the 3 groups of animals showed an increase in the levels 
from that of baseline but were not to the level of significance.  
 Following treatment all the 3 groups of animals revealed a statistically 
significant reduction in serum NF-κB levels [P=0.043, 0.001, 0.027] [Table-4]. 
As of now, there are only 3 studies done with the objective of establishing the 
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role of M.charantia on pro-inflammatory marker NF-κB, one being the work 
done to demonstrate the inhibitory activity of M.charantia as one of the tested 
compounds on NF-κB transcriptional activation in HepG2 cells (human hepato-
carcinoma) in Dulbecco‟s modiﬁed Eagle‟s medium had proven its inhibitory 
effect
209
. Another was an m-RNA study on heart tissue of the obese Zucker rats 
demonstrated that down-regulation of nuclear factor-κB (NF-κB), and 
interferon-γ by M.charantia210. The third being an electrophoretic mobility 
shift assay with the ethanol extracts and the hot aqueous extracts of 
M.charantia showing inhibition of NF-κB activation211. But so far no research 
is done to assess the effect of M.charantia extract in vivo on serum NF-κB 
levels. 
 The histopathological examination of the liver and heart was done in 
our study.  Due to liability of ethical concern, we have taken the pictures of 
diseased liver and heart in response to fructose intake from standard research 
articles. In comparison to normal control all the liver showed fatty infiltration, 
both microvesicular and macrovesicular steatosis that was in ordinance to high 
fructose diet as apparent in prior studies. In addition, the changes in 
histopathology of the liver and heart by M.charantia unlike that of pancreas, 
has not been studied in literature till date. 
 In distinction, the fatty change that was observed in these groups in 
comparison to the diseased picture revealed a significantly minimal change. 
There also exists a difference in fatty changes among groups, HPE of liver of 
Group I showed maximum change of grade 3+ while that of Groups II and III 
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were presented with only grade 2+ changes [Figure-25-Annexure]. 
 So far there are no studies dealt on the role of M.charantia on the fatty 
changes precipitated on consumption of the fructose. So ours is the first work 
done to learn the changes, and we obtained an affirmative result that the 
changes in both M.charantia high dose and standard treatment groups were 
homogenous and the fatty change in these groups were of a lower degree in 
comparison to the low dose M.charantia group. 
 In comparison to normal control all the heart HPE sections showed 
hypertrophy that was in accordance to previous studies with reference to high 
fructose diet.  
 The cardiac hypertrophy was highly evident but observations made in 
these 3 groups were homogenous with no difference among them. The reason 
for this could duly be explained by the relatively brief span of treatment was 
not sufficient to bring about the scale of expected changes in the hypertrophied 
myocytes. But the positive finding illustrated was that the fatty change 
observed in the picture of disease control was not evident in the HPE sections 
of all three groups of treated animals. So, further studies pertaining to this 
could be done in future to assess the effect of Momordica on progression of 
cardiac hypertrophy [Figure-26-Annexure]. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Conclusion 
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CONCLUSION: 
 High fructose diet (66%)was affirmatively found to be the animal model 
appropriate for inducing metabolic syndrome to study the effect of drugs as 
the model effectively reproduced all the metabolic changes [BMI,FBS,BP, 
Lipid parameters]seen in the syndrome. 
 We included two different doses of M.charantia, of which 600mg/kg/day 
had exclusively matched the therapeutic efficacy of the standard therapy 
given in combination. 
 M.charantia’s efficacy in a chronic inflammatory disease like metabolic 
syndrome is successfully demonstrated in our study with respect to 
reduction of inflammation and oxidative stress evidenced by a decline in 
serum NF-κB and LDA along with increased free radical scavenger, SOD. 
 The biological basis of the effects of M.charantia by inhibiting the 
inflammatory pathway in metabolic syndrome both at the levels of ROS 
generation and transcription of pro-inflammatory marker NF-κB was 
proven. 
 The histopathological examination findings has imparted that metabolic 
syndrome is a multi-organ inflammatory disease condition inducing 
detectable pathological changes in various organs like liver and heart and 
that M.charantia is a potentially effective agent to reverse such significant 
changes. 
  
 
 
 
 
 
 
 
 
 
 
Annexure 
 
Table-1: Paired sample t-test of Body weight, BMI, Fasting blood sugar 
PARAMETERS GROUPS PAIRS MEAN SD SEM 
CI 
t P 
LOWER UPPER 
 
 
BODY 
WEIGHT 
 
I 
Baseline-Induction -134.8 33.31 10.53 -158.63 -110.97 -12.796 <0.001 
Induction-Treatment 5.81 16.26 5.14 -5.82 17.44 1.130 0.288 
 
II 
Baseline-Induction -147.9 23.53 7.44 -164.73 -131.07 -19.877 <0.001 
Induction-Treatment 11.10 10.91 3.45 3.29 18.90 3.218 0.011 
 
III 
Baseline-Induction -125.75 11.44 3.62 -133.94 -117.57 -34.767 <0.001 
Induction-Treatment 0.50 12.14 3.84 -8.18 9.18 0.130 0.899 
 
 
BMI 
 
I 
Baseline-Induction -0.24 0.97 0.31 -0.31 -0.17 -7.800 <0.001 
Induction-Treatment 0.07 0.08 0.03 0.01 0.13 2.785 0.021 
 
II 
Baseline-Induction -0.28 0.59 0.19 -0.33 -0.24 -15.129 <0.001 
Induction-Treatment 0.06 0.03 0.01 0.04 0.08 6.192 <0.001 
 
III 
Baseline-Induction -0.23 0.39 0.12 -0.26 -0.20 -18.768 <0.001 
Induction-Treatment 0.04 0.05 0.01 0.01 0.07 2.816 0.020 
 
 
FBS 
 
I 
Baseline-Induction -95.30 16.93 5.35 -107.41 -83.19 -17.806 <0.001 
Induction-Treatment 51.37 18.23 5.76 38.33 64.41 8.912 <0.001 
 
II 
Baseline-Induction -89.60 23.09 7.30 -106.12 -73.08 -12.27 <0.001 
Induction-Treatment 73.12 25.19 7.97 55.09 91.15 9.177 <0.001 
 
III 
Baseline-Induction -93.25 18.20 5.76 -106.27 -80.23 -16.20 <0.001 
Induction-Treatment 73.12 25.19 7.97 55.09 91.15 9.177 <0.001 
  
Table-2: Paired sample t-test of MAP, Triglycerides, Total cholesterol 
PARAMETERS GROUPS PAIRS MEAN SD SEM 
LOWER 
CI 
UPPER 
CI 
t P 
 
 
 
MAP 
 
I 
Baseline-Induction -34.63 51.93 18.36 -78.04 8.79 -1.886 0.101 
Induction-Treatment -8.41 60.85 21.51 -59.28 42.46 -0.391 0.707 
 
II 
Baseline-Induction -14.25 38.16 13.49 -46.15 17.65 -1.056 0.326 
Induction-Treatment 28.71 53.59 18.95 -16.09 73.51 1.515 0.173 
 
III 
Baseline-Induction -57.50 41.31 14.61 -92.04 -22.96 -3.937 0.006 
Induction-Treatment 49.83 64.57 22.83 -4.15 103.81 2.183 0.065 
 
 
 
TGL 
 
I 
Baseline-Induction -158.35 89.83 31.76 -233.45 -83.24 -4.986 0.002 
Induction-Treatment 176.16 95.14 33.64 96.62 255.70 5.237 0.001 
 
II 
Baseline-Induction -125.68 35.45 12.53 -155.31 -96.04 -10.027 <0.001 
Induction-Treatment 132.99 29.69 10.49 108.17 157.82 12.667 <0.001 
 
III 
Baseline-Induction -202.05 73.85 26.11 -263.79 -140.31 -7.739 <0.001 
Induction-Treatment 235.78 77.08 27.25 171.33 300.22 8.651 <0.001 
 
 
 
TC 
 
I 
Baseline-Induction -107.05 42.89 16.21 -146.72 -67.38 -6.603 0.001 
Induction-Treatment 25.61 32.87 12.42 -4.79 56.01 2.061 0.085 
 
II 
Baseline-Induction -119.13 24.45 9.24 -141.75 -96.52 -12.89 <0.001 
Induction-Treatment 78.77 35.81 13.54 45.65 111.89 5.819 0.001 
 
III 
Baseline-Induction -108.05 10.13 3.83 -117.42 -98.68 -28.22 <0.001 
Induction-Treatment 70.80 28.12 10.63 44.79 96.81 6.661 0.001 
  
Table-3: Paired sample t-test of LDL,HDL,TBARS 
PARAMETERS GROUPS PAIRS MEAN SD SEM 
LOWER 
CI 
UPPER 
CI 
t P 
 
 
 
LDL 
 
I 
Baseline-Induction -104.97 26.43 9.99 -129.41 -80.52 -10.507 <0.001 
Induction-Treatment 28.98 78.38 29.62 -43.50 101.47 0.978 0.366 
 
II 
Baseline-Induction -135.78 20.11 7.59 -154.38 -117.19 -17.868 <0.001 
Induction-Treatment 80.62 29.74 11.24 53.12 108.13 7.172 <0.001 
 
III 
Baseline-Induction -113.04 13.82 5.22 -125.83 -100.26 -21.635 <0.001 
Induction-Treatment 32.09 9.38 3.54 23.42 40.76 9.056 <0.001 
 
 
 
HDL 
 
I 
Baseline-Induction 32.03 9.87 3.12 24.97 39.09 10.258 <0.001 
Induction-Treatment -10.84 3.25 1.03 -13.17 -8.51 -10.544 <0.001 
 
II 
Baseline-Induction 41.46 1.83 0.58 40.15 42.76 71.78 <0.001 
Induction-Treatment -23.56 10.09 3.19 -30.77 -16.34 -7.383 <0.001 
 
III 
Baseline-Induction 45.85 4.31 1.36 42.76 48.93 33.661 <0.001 
Induction-Treatment -2.29 1.80 0.57 -3.57 -0.99 -4.011 0.003 
 
 
 
TBARS 
 
I 
Baseline-Induction -2.59 1.95 0.69 -4.22 -0.96 -3.760 0.007 
Induction-Treatment 1.24 1.62 0.57 -0.11 2.59 2.172 0.066 
 
II 
Baseline-Induction -3.19 1.75 0.62 -4.65 -1.73 -5.170 0.001 
Induction-Treatment 2.71 2.67 0.95 0.47 4.94 2.861 0.024 
 
III 
Baseline-Induction -3.47 2.14 0.76 -5.26 -1.68 -4.589 0.003 
Induction-Treatment 2.98 1.49 0.53 1.72 4.23 5.612 0.001 
  
Table-4: Paired sample t-test of SOD, NFκB 
PARAMETERS GROUPS PAIRS MEAN SD SEM 
LOWER 
CI 
UPPER 
CI 
t P 
 
 
 
SOD 
 
I 
Baseline-Induction 0.70 0.39 0.14 0.37 1.03 5.086 0.001 
Induction-Treatment -0.34 0.48 0.17 -0.74 0.06 -1.991 0.087 
 
II 
Baseline-Induction 0.52 0.37 0.13 0.22 0.83 4.036 0.005 
Induction-Treatment -0.46 0.70 0.25 -1.05 0.13 -1.849 0.107 
 
III 
Baseline-Induction 1.24 0.45 0.16 0.86 1.62 7.711 <0.001 
Induction-Treatment -0.35 0.73 0.26 -0.96 0.26 -1.367 0.214 
 
 
 
NFκB 
 
I 
Baseline-Induction -8.22 19.30 7.29 -26.07 9.63 -1.127 0.303 
Induction-Treatment 16.12 16.70 6.31 0.67 31.57 2.553 0.043 
 
II 
Baseline-Induction -6.95 15.13 5.72 -20.93 7.04 -1.215 0.270 
Induction-Treatment 22.15 8.76 3.31 14.05 30.26 6.688 0.001 
 
III 
Baseline-Induction -3.53 8.76 3.31 -11.64 4.57 -1.066 0.327 
Induction-Treatment 14.35 13.02 4.92 2.31 26.39 2.915 0.027 
 
Table 5: ANOVA- Body weight between groups at treatment [12 weeks] 
Parameter Groups Mean square F Sig 
Body weight  Between Groups 621.273 2.780 0.055 
Within Groups 223.480   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
Body weight  
IV & I -18.9478 8.1698 0.425 
IV & II -32.0588 -4.9412 0.009 
IV & III -24.1848 2.9328 0.121 
 
Table 6: ANOVA-BMI between groups at treatment [12 weeks] 
Parameter Groups Mean square F Sig 
BMI   
Between Groups 0.003 2.552 0.071 
Within Groups 0.001   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
BMI    
IV & I -.01891 .04251 .441 
IV & II -.05961 .00181 .064 
IV & III -.03741 .02401 .661 
 
Table 7: ANOVA- Fasting blood sugar between groups at treatment [12 weeks] 
Parameter Groups Mean square F Sig 
FBS    
Between Groups 1107.475 5.631 .003 
Within Groups 196.672   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
FBS    
IV & I -36.8886 -11.4494 .000 
IV & II -20.0556 5.3836 .250 
IV & III -17.4316 8.0076 .457 
 
 
 
 
Table 8: ANOVA- MAP between groups at treatment [12 weeks] 
Parameter Groups Mean square F Sig 
MAP  
Between Groups 2976.248 1.810 .168 
Within Groups 1644.284   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
MAP  
IV & I -80.4162 2.6462 .065 
IV & II -38.7962 44.2662 .894 
IV & III -60.1312 22.9312 .367 
 
Table 9: ANOVA- Triglycerides between groups at treatment [12 weeks]  
Parameter Groups Mean square F Sig 
TGL  
Between Groups 222.766 3.463 0.029 
Within Groups 64.331   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
TGL  
IV & I -13.7673 2.6623 .177 
IV & II -11.9861 4.4436 .355 
IV & III -1.8386 14.5911 .123 
 
Table 10: ANOVA- Total Cholesterol between groups at treatment [12 weeks]
  
Parameter Groups Mean square F Sig 
TC    
Between Groups 4545.053 8.680 .000 
Within Groups 523.603   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
TC     
IV & I -84.5067 -34.0190 .000 
IV & II -44.6553 5.8324 .126 
IV & III -38.7038 11.7838 .282 
 
 
 
Table 11: ANOVA- LDL Cholesterol between groups at treatment [12 weeks] 
Parameter Groups Mean square F Sig 
LDL    
Between Groups 2301.965 1.976 .144 
Within Groups 1164.702   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
LDL    
IV & I -79.3154 -4.0160 .032 
IV & II -50.8511 24.4483 .476 
IV & III -66.2483 9.0511 .130 
 
Table 12: ANOVA- HDL Cholesterol between groups at treatment [12 weeks]
  
Parameter Groups Mean square F Sig 
HDL    
Between Groups 968.201 25.175 .000 
Within Groups 38.459   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
HDL    
IV & I 5.0063 16.2557 .000 
IV & II -6.3027 4.9467 .808 
IV & III 14.4263 25.6757 .000 
 
Table 13: ANOVA- TBARS between groups at treatment [12 weeks]  
Parameter Groups Mean square F Sig 
TBARS     
Between Groups 1.905 1.272 .303 
Within Groups 1.497   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
TBARS    
IV & I -2.3746 .1321 .078 
IV & II -1.4558 1.0508 .743 
IV & III -1.7183 .7883 .454 
 
 
 
Table 14: ANOVA- SOD between groups at treatment [12 weeks]  
Parameter Groups Mean square F Sig 
SOD    
Between Groups 1.037 3.089 .043 
Within Groups .336   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
SOD   
IV & I -.1920 .9945 .177 
IV & II -.1920 .9945 .177 
IV & III .2867 1.4733 .005 
 
Table 15: ANOVA- Serum NF-κB between groups at treatment [12 weeks]  
Parameter Groups Mean square F Sig 
NF-κB     
Between Groups 83.359 2.949 .053 
Within Groups 28.265   
 
Parameter Groups 
Confidence Interval 
Sig 
Lower Upper 
NF-κB        
IV & I -6.7766 4.9537 .751 
IV & II -4.3380 7.3923 .596 
IV & III .9420 12.6723 .025 
 
Figure-25: Histopathological examination of Liver [H&E] staining 
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 Figure-25: Histopathological examination of Heart [H&E] staining 
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FIgure 27: Illustration of obesity following induction of metabolic syndrome in rats 
 
 
 
Figure 28:Estimation of NF-κB by ELISA Kit 
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NHANES - National Health and Nutrition Examination Survey  
WHO        - World Health Organization 
IDF           - International Diabetes Federation  
NCEP       -National Cholesterol Education Program  
ATPIII    - Adult Treatment Panel III 
FFAs         - Free fatty acids 
IRS1          - Insulin receptor substrate 1-kinase  
NF-κB       - Nuclear factor kappa B 
ROS           - Reactive oxygen species  
LDA          -Lipid peroxidation derived aldehydes 
MDA         - Malondialdehyde 
SOD          - Superoxide dismutase  
AMPK       - Adenosine monophosphate activated protein kinase  
PPAR        - Peroxisome proliferator activated receptor 
AGEs         - Advanced glycation end products  
NIBP         - Non-invasive blood pressure  
IDF           - International Diabetes Federation 
CAPPP     - Captopril Prevention Project  
HOPE       - Heart Outcomes Prevention Evaluation  
LIFE         - Losartan Intervention for Endpoint Reduction   
VALUE    - Valsartan Antihypertensive Long-term Use Evaluation  
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